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ABSTRACT 
Cervical cancer is a major problem in the developing world and low-
resource settings where standard screening techniques are not accessible. 
Cervical cancer is one of the few cancers that can be successfully treated when 
detected early. Therefore, there exists a high clinical need to screen for cervical 
cancer early. The etiological agent of cervical cancer is the human papillomavirus 
(HPV), with 70% of cases related to HPV genotypes 16 and 18.  
I sought to increase access to screening by developing a fully integrated 
and multiplexed molecular diagnostic assay to extract, amplify, detect, and 
distinguish HPV16 and HPV18 DNA on a low-cost paperfluidic platform for point-
of-care (POC) applications. Isothermal (one temperature) loop-mediated 
amplification (LAMP) was used to amplify HPV DNA instead of the traditional 
polymerase chain reaction (PCR) that requires multiple temperatures. The 
amplified HPV16 and HPV18 DNA were differentially detected on a simple lateral 
flow strip – similar to that used in a pregnancy test – generating a visible 
colorimetric readout for each specific genotype.  
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LAMP amplification is difficult to characterize and current methods were 
insufficient in providing specificity at the level needed for a multiplexed assay. 
Therefore, a novel characterization strategy was developed based on fluorescence 
to distinguish positive LAMP amplification products. This workflow used differential 
fluorescent tags to identify whether HPV16 DNA or HPV18 DNA was present and 
simplified complex nonspecific LAMP smears to a specific band pattern.  
After singleplex HPV16 and HPV18 LAMP assays were optimized with the 
new workflow, the two singleplex assays were successfully combined into one 
multiplex reaction with 12 primers, a nontrivial feat. Each assay step  – DNA 
extraction, amplification, and detection  – was optimized and integrated into a 
single chip that can control the timing of each step. Several chip configurations 
were tested to determine the optimal chip form factor, and a small subset of clinical 
samples were tested to demonstrate feasibility in low-resource settings. With this 
diagnostic platform, asymptomatic patients positive for HPV16 DNA and HPV18 
DNA can be screened more closely, allocating precious resources to those most 
at risk, a beneficial use in both low-resource settings and the USA.  
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Chapter 1: Introduction and Thesis Aims 
 
1.1 Overarching goals and thesis aims 
The purpose of this thesis work was to develop a multiplexed, portable, 
inexpensive platform to differentially detect HPV16 and HPV18 DNA from cervical 
swab samples. To achieve this goal, I proposed three aims: 
 
Specific Aim 1: Design singleplex loop-mediated amplification (LAMP) 
assays for human papillomavirus (HPV) 16 and HPV18 in tube 
I designed new LAMP primers for HPV16 LAMP and optimized previously 
published primers for HPV18 LAMP to operate at a reaction time of 30 minutes, 
which is more appropriate for use in a low-resource setting. A new fluorescence 
imaging workflow was developed to characterize exactly which LAMP amplicons 
(products) were binding to the lateral flow strip. 
 
Specific Aim 2: Develop multiplexed LAMP (mLAMP) in tube 
 Restriction enzyme-digested products for each singleplex LAMP assay from 
Aim 1 were extracted and sequenced to confirm reaction specificity. The two 
singleplex LAMP assays were combined to form one multiplexed LAMP (mLAMP) 
reaction. This tube reaction was optimized and translated to a chip platform that 
was suitable for the low-resource setting in Aim 3.  
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Specific Aim 3: Optimize chip for clinical samples 
Clinical samples were characterized with an optimized quantitative PCR 
(qPCR) protocol for HPV16, HPV18, and RNAseP. Chip materials and 
configurations were investigated to determine optimal chip conditions for LAMP. 
The mLAMP tube assay from Aim 2 was translated to the optimal Fellowes 
adhesive chip as 2 separate reactions. The optimized chip configuration was 
QIAGEN extraction and Fellowes chip for amplification and detection of clinical 
samples. A small set of clinical samples was tested to demonstrate feasibility of 
the optimized chip. 
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1.2 Cervical cancer background 
Cervical cancer is the fourth most common cancer in women worldwide and 
kills 266,000 women per year. 1 Approximately 87% of these cases are in 
developing countries where there are limited resources for screening, as 
demonstrated by the blue regions below (Figure 1). 1  
 
Figure 1: Cervical cancer incidence worldwide. 
 
When diagnosed early and accurately, cervical cancer has a high cure rate, 
emphasizing the value of early detection. The fundamental goal of cervical cancer 
screening is to differentiate cervical intraepithelial neoplasia III (CIN-3), the 
immediate precursor lesion that will likely progress to cervical cancer, from benign 
lesions that will most likely not become cancerous. The ideal screening platform 
should maximize the benefits and minimize the potential harms of screening. The 
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benefits of accurate screening are the true positive and true negative results that 
provide the patient with a relatively high degree of certainty if they do or do not 
have precancerous lesions, respectively. The harms of screening are the false 
positives and false negative results. In both of these cases, the patient is 
misinformed and thus at a higher risk than if they did not get screened. False 
positive patients will get unnecessarily or overly treated when they do not have a 
precancerous lesion while false negative patients will have precancerous lesions 
that will go untreated or unchecked.  
The screening mechanism I implemented detects the presence of the 
human papillomavirus (HPV) D, specifically the high-risk genotypes 16 and 18, as 
chronic infection with these genotypes is strongly correlated with cervical cancer.2 
HPV is a DNA virus that produces infections in mucous membranes or 
keratinocytes of the skin and leads to an increased risk for developing cervical 
cancer. In fact, almost 99% of cervical cancer cases are due to HPV, with 55-60% 
from HPV16 and 10-15% from HPV18, making them the two most common high-
risk(hr) HPVs worldwide.3  HPV16 is the dominant HPV genotype where high levels 
are associated with cervical cancer progression. HPV18 has been found to cause 
a greater proportion of adenocarcinomas instead of squamous cell carcinomas 
(32% vs 8%, respectively3).  
The biology of cervical carcinogenesis involves HPV acquisition, HPV 
persistence (versus clearance), progression to cancer, and invasion/cancer. 
Transient HPV infections are very common in the population, especially if one is 
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sexually active. However, 90% of people infected with HPV clear the virus within 
1-2 years and are not at increased risk for cervical cancer.2,4 Those who do not 
clear the virus have an increased risk of developing precancerous lesions (CIN 1-
3) and ultimately cervical cancer. This progression to cervical cancer usually takes 
decades, whereby the virus lies dormant and undetectable with standard HPV 
tests, which is why routine cervical cancer screening is important. Cervical cancer 
develops slowly and has a high cure rate if treated in the early stages, so deaths 
from cervical cancer can be prevented with proper screening and detection of 
precancerous lesions. 
However, as HPV testing is expanding and women are acquiring HPV test 
histories over time, there is more data that suggests a potential shift in the 
carcinogenesis model. There is a growing trend of intermittent HPV positive and 
generally HPV negative results, which indicates a new mechanism where latent 
HPV infections get re-activated. This suggest carcinogenesis is an interplay 
between latency and activation, which depends on factors like menstrual cycle and 
microbiome transitions, and not as generally expected, sexual activity or sexual 
partners. Thus, it is important for HPV negative women to also get tested for HPV 
regularly in case the infection gets activated. The notion of viral clearance is being 
replaced with that of latency/dormancy and reactivation. 5 Therefore, there is an 
even more pressing need to HPV testing to be accessible because an HPV 
negative result has a lower negative predictive value than was previously 
characterized.  
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1.3 Current cervical cancer screening techniques 
The traditional screening method for cervical cancer is the Papanicolaou 
(Pap) smear, which is based on cytology. Trained pathologists examine cervical 
smear samples under the microscope and determine if cells look normal or 
abnormal, particularly in the transformation zone of the cervix. The Pap smear was 
introduced by George Papanicolaou in 1949 before the link between genital HPV 
infections and cervical cancer was first demonstrated in the early 1980s by Harald 
zur Hausen. This qualitative and subjective process does not detect HPV. Although 
there is high specificity for cancer (96.3%), the sensitivity of the Pap smear (53%) 
is low.6 Additionally, the Pap smear is often not suitable for low-resource settings 
where there are not (enough) trained personnel or appropriate equipment 
(microscope, central laboratory) and the laboratory is located far away from the 
patient or clinic. Samples are usually collected and stored before transported to a 
central lab to be batch-processed. As a result, it can take weeks to turn around a 
result to the patient. Loss to follow-up is a common problem in low-resource 
settings because it may not be possible to locate the patient again to deliver the 
results. Thus, there is a significant need to develop a low cost, robust screening 
tool for cervical cancer that can return the answer to the patient in the same visit 
on the order of minutes to hours.  
A more suitable screening method for low-resource settings is visual 
inspection with acetic acid (VIA). This provides direct visualization of cervical cells 
without a microscope and can be performed in the doctor’s office. 5% acetic acid 
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(vinegar) is applied to the cervix, and after 30-60 seconds, pre-cancerous cells turn 
white due to the presence of more intracellular proteins while normal cells do not 
change color. The sensitivity of VIA (96.7%) is similar to or higher than the Pap 
smear (53%), but the specificity is low, leading to overtreatment.7 It is also 
cytology-based and does not provide molecular information about the cells. An 
advantage of VIA is results are provided during the same visit, thus eliminating the 
loss to follow-up that can occur with the Pap smear. If a lesion is detected, the 
lesion can be removed in the same visit using cryotherapy or large loop excision 
of the transformation zone (LEEP).  
The World Health Organization (WHO) recommends a “screen and treat” 
approach for cervical cancer prevention in which a treatment decision is based on 
a screening test and treatment is provided soon or, ideally, immediately after a 
positive screening test. 8 This is a more realistic alternative to the conventional 
screening and diagnostic sequence of cytology, colposcopy, biopsy, and 
histological confirmation of cervical intraepithelial neoplasia (CIN), which can be 
especially difficult to implement in low-resource settings. For low-resource settings 
where HPV testing is not available, the WHO recommends VIA over cytology (Pap 
smear), followed by cryotherapy treatment (Recommendation 3). However, for 
settings where HPV testing is available, the WHO recommends HPV testing over 
VIA, followed by cryotherapy treatment (Recommendation 2). Therefore, there is 
an unmet need to provide a less resource-intensive HPV test for low-resource 
settings. 
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1.4 Using HPV to detect cervical cancer  
HPV infection and the link to cervical cancer 
In recent years, there has been growing evidence validating the use of HPV 
DNA detection as an alternative screening method to the Pap smear and VIA. HPV 
was first linked to cervical cancer by Harald zur Hausen in 1983. He successfully 
isolated and characterized HPV169 and HPV1810 from cervical cancer biopsies, 
and found that viral DNA existed in an integrated state into the genome.  
HPV16 and HPV18 viral genomes encode the E6 and E7 oncogenes which 
produce proteins to initiate and maintain neoplastic growth of epithelial cells. The 
E7 oncogene is activated early on in the HPV life cycle. Integration of the E7 gene 
into the host genome has been associated with progression to invasive cancer. 11  
E7 is the primary transforming protein that causes progression from precancer to 
cancer as the HPV-infected cells travel from the basal membrane to the epithelial 
layer of the cervix. 
Hausen found that the E6 and E7 genes were consistently transcribed in 
the cancer cells and precursor lesions also had the HPV16 and HPV18 viruses 
and expressed the E6 and E7 genes. His work on papillomaviruses as the cause 
of cervical cancer was fundamental to the development of the preventative HPV 
vaccine and contributed to him receiving the Nobel Prize in Physiology in 2008. 12 
Almost 99% of cervical cancer cases are due to HPV, with 55-60% from 
HPV16 and 10-15% from HPV18, making them the two most common high-risk 
HPVs worldwide. 3,13 Together, HPV16 and 18 are responsible for 70% of cervical 
 9 
cancers. 2 HPV16 has a preferential risk to develop into cervical squamous cell 
carcinoma (SCC) while HPV18 has a preferential risk to develop into cervical 
adenocarcinoma (AC). 14 In addition, distinguishing HPV16 from HPV18 can be 
valuable because HPV18 has been associated with poorer prognosis and higher 
likelihood of relapse. 15, 16 
 
HPV DNA detection strategies 
Given the limitations of cytology, much work has been focused recently on 
molecular diagnostics for cervical cancer. HPV DNA testing offers the advantages 
of high sensitivity (>96%) and specificity (>90%).6 However, current HPV tests 
require sophisticated instrumentation to provide pressure-driven fluid handling, 
cyclic thermal control, and optical assay detection, resulting in expensive 
equipment, costly disposables, and long reaction times (hours) that are not suitable 
for low-resource settings that have minimal healthcare infrastructure.  
The first HPV DNA test approved by the FDA in 1999 was the QIAGEN 
Digene Hybrid Capture II (HC2) test, which is based on the chemiluminescent 
detection of RNA probes hybridizing to target HPV DNA. This assay is performed 
in a laboratory with a plate reader and can take ~6 hours.  Sankaranarayanan et 
al. found that patients who were screened with the Digene HPV test had ~50% 
lower incidence of advanced cancers and mortality over a lifetime compared to 
those screened with cytology or VIA.17 This landmark paper validated the use of 
HPV DNA testing but acknowledged its drawbacks of high cost and need for 
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sophisticated laboratory equipment. Therefore, a lower cost version of the Digene 
test – careHPV – was developed by PATH and QIAGEN for use in low-resource 
settings specifically. This platform uses similar technology as the Digene HC2 test 
but takes approximately 4 hours and requires benchtop space. In addition, it is 
designed to be run in batch mode, with optimal use at 90 samples per batch. This 
high screening volume is very difficult for clinics in low-resource settings to achieve 
in a single day, thereby preventing same-day diagnosis and treatment.  
Another molecular diagnostic test is the Cervista test, which was approved 
by the FDA in March 2009. It evaluates 14 of the most common high-risk HPV 
genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) using 
Invader Chemistry, a signal amplification method to detect specific nucleic acid 
sequences. There are two isothermal reactions: a primary reaction that occurs on 
the targeted DNA sequence and a secondary reaction that produces a 
fluorescent signal. The use of isothermal reactions simplifies the thermal cycling 
requirement found in polymerase chain reaction (PCR) amplification-based tests, 
but there is still considerable complexity with the requirement of fluorescent 
probes and fluorescence detection instrument.  
The cobas® HPV test (Roche, Basel, Switzerland) was approved by the 
FDA in 2014 as a first-line screening alternative to the Pap smear for women 25 
and older. The test provides specific genotyping information for HPV16 and 
HPV18 while detecting 12 other high-risk HPV types. Target HPV DNA is 
amplified using PCR – thus requiring multiple temperatures – and hybridized to 
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probes for detection. The test is automated on the cobas® 4800 system, a large, 
resource-intensive machine that is not suitable for the POC. 
 
Advantages of HPV DNA testing  
The largest HPV screening trial in the USA was the ATHENA (Addressing 
THE Need for Advanced HPV Diagnostics) study that included more than 47,000 
women who underwent routine cytology and HPV testing. The study demonstrated 
that HPV testing had higher sensitivity than liquid-based Pap cytology in identifying 
CIN-3, the pre-cancerous lesion that typically leads to cervical cancer. 18 25% of 
women who were HPV16 positive had cervical disease within three years and 1 in 
7 women with normal Pap cytology who were HPV16 positive had high-grade 
cervical disease that was missed by cytology. 18,19 There have been numerous 
studies since that corroborate the increased sensitivity of the HPV test over the 
Pap smear. 4,20-23 A recent study showed that patients who underwent a single HPV 
screening had better outcomes than patients who did not have HPV screening and 
that the HPV test was more cost-effective than the Pap or VIA. 24,25  
The HPV DNA test has a greater negative and positive predictive value than 
the Pap smear when performed separately as well as jointly with the Pap smear. 
26-30 A major study done by Castle et al. 27 followed 19,512 women for more than 
10 years to study the long-term benefits of HPV testing in regards to pre-cancer 
detection and cancer risk detection. A notable finding from this study was that only 
HPV testing predicted which patients would develop CIN-3 10-18 years after the 
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initial screening. HPV-positive women were more likely to be diagnosed with CIN-
2 or CIN-3 than HPV-negative women, but this trend was not true for Pap-positive 
women, who had the same likelihood of developing CIN-2 or CIN-3 than Pap-
negative women.  
Katki et al. followed 331,818 women over 5 years to assess how their 
diagnostic results from the Pap smear or HPV test correlated with their incidence 
of CIN-3+.28 Their work (Figure 2) showed that an HPV-positive result correlated 
to a higher incidence of CIN-3+ than a Pap-positive result, suggesting that an HPV-
positive result was more likely to predict CIN-3+ than a Pap-positive result. 
Similarly, an HPV-negative result correlated to a lower incidence of CIN-3+ than a 
Pap-negative result, suggesting that an HPV-negative result was more likely to 
predict not developing CIN-3+ than a Pap-negative result.  
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These trends were further corroborated when women had joint diagnoses 
from the HPV test and the Pap smear (Figure 2). Women who were HPV-positive 
and Pap-positive had the highest incidence of CIN-3+ of 12.1% after 5 years. 
However, women who were HPV-positive but Pap-negative had an incidence of 
5.9% after 5 years. If screened by Pap only, the CIN-3+ risks of these women 
would’ve been missed. This demonstrated that the positive HPV test had a 
stronger correlation to development of CIN-3+ than the Pap smear. The third 
subset of women was HPV-negative and Pap-positive. Their incidence of CIN3+ 
was low, showing that a Pap-positive result was not well-correlated to development 
of CIN-3+, but that an HPV-negative result was. This result was further confirmed 
in the last subset of women who were HPV-negative and Pap-negative and had 
the lowest incidence of CIN3+ after 5 years.  
Therefore, detecting HPV DNA is an encouraging alternative to the Pap 
smear. It has lower subjectivity, higher sensitivity, and similar specificity than the 
Pap smear. In addition, the HPV test has a strong negative predictive value. 
Numerous studies have found that an HPV-negative result was a better predictor 
than a Pap-negative result for whether a patient will develop CIN-3+ 3-6 years after 
initial screening. 29,31-33 
However, as with Pap smears, current HPV DNA tests require highly trained 
personnel and a high turnaround time of hours to days, depending on how far the 
sample has to travel to a central laboratory. In addition to these technical 
requirements, the need for resource-intensive equipment such as thermal cyclers, 
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sample processing instruments, and plate readers further prevents their use at the 
POC, especially in low-resource settings.  
 
Translating the HPV test to the POC 
Translating the HPV test to the POC can minimize these limitations by 
providing results faster, on the order of minutes instead of hours, allowing doctors 
to diagnose, advise, and potentially treat in the same visit.  Asymptomatic patients 
positive for HPV16 and HPV18 could be screened more closely, thus allocating 
precious resources to those most at risk.  In addition, a POC device could be taken 
to remote settings beyond a standard clinic or laboratory because reagents are 
self-contained or portable, allowing more patients to be screened.  
With early detection, cervical cancer can be successfully treated. A POC 
microfluidic chip to detect HPV could increase access to screening and early 
detection for patients, especially in low-resource settings where a follow up visit is 
difficult to achieve, improving their quality of life and reducing mortality from late 
detection. In addition, new POC technologies such as multiplex targeting have the 




1.5 Loop-mediated Amplification (LAMP) 
 Loop-mediated amplification (LAMP) is an isothermal nucleic acid 
amplification technique that is an alternative to PCR, which requires multiple 
temperatures for amplification. Isothermal amplification techniques remove the 
need for DNA denaturation (the first step in PCR) and allows for single-temperature 
amplification of nucleic acids. LAMP uses a DNA polymerase called Bst 
polymerase that has strand displacement activity. LAMP eliminates the need for 
thermal cycling and dramatically reduces the cost of amplification as the reaction 
can be carried out at a constant temperature of 63°C. The simplicity of use, rapidity 
(results can be obtained within 30 minutes), and excellent sensitivity and 
specificity36,37 make LAMP suitable for low-resource settings. The sensitivity and 
specificity of LAMP are due to its use of six primers that are carefully designed to 
amplify specific regions on the target DNA to generate a stem loop “dumbbell” 
structure that serves as the starting material for exponential amplification.  
In the LAMP schematic (Figure 3), the original target DNA strand is shown 
in green, with the target regions for each primer in blue (F3, F2, F1) and red (B1c, 
B2c, B3c). There are two inner primers (Forward and Backward Inner Primers, FIP 
and BIP), two outer primers (Forward and Backward 3, F3 and B3), and two loop 
primers (Loop Forward and Backward, LF and LB). The inner primers are 
composed of two components – one component (F2 or B2) binds to the target DNA 
while the other component (F1c or B1c) does not bind to the target DNA and 
instead, creates the stem loop structure critical for downstream cycle extension. 
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The F1c or B1c region forms a loop by binding to the complementary region (F1 or 
B1) on the original target DNA. This is shown in step 4 where B1c from BIP bound 
to B1 and generated a loop for LB to bind to. 
Extension begins when an inner primer (FIP or BIP) binds to the target DNA. 
The appropriate outer primer then displaces this amplified strand, making the 
target DNA available for another inner primer to bind and freeing the displaced 
amplified strand to serve as a template for subsequent extension. The loop primer 
binds to the stem loop, which is only formed from an inner primer-initiated amplified 
strand. This process repeats in the forwards and backwards directions. Self-
priming allows extension to occur continuously after the dumbbell is formed (B1 
self-priming and displacing F1c from F1 in step 6). The rapidity of LAMP is due to 
the strands polymerizing and displacing simultaneously, which generates a high 
amount of product in a short amount of time. Most importantly, there are several 
types of amplicons at the end of a LAMP reaction, as opposed to only one amplicon 
for PCR, because different primers initiate extension and strand displacement 
occurs stochastically. This results in a ladder-like smear on an agarose gel as 




Figure 3: Schematic of LAMP amplification (Nagamine et al.). 
 
Challenges in LAMP characterization 
 The amplicons after a LAMP reaction are a complex mixture of products of 
different sizes which is difficult to characterize. Having 6 primers, let alone 12 
primers as I eventually want in the multiplexed LAMP reaction, of 20-40 bp length 
in a reaction leads to a high chance of nonspecific amplification and false 
positives. This ultimately limits the use of LAMP as a technique.  
Current LAMP characterization methods are insufficient in determining 
specificity of the amplicons. The first and most commonly used method is 
agarose gel electrophoresis, where in the presence of DNA, there is a smear of 
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products of different size and in the absence of DNA, there is a single band of 
unextended primers (Figure 4). 38 
 
Figure 4: Agarose gel characterization of LAMP products (adapted from Zhang et al.). 
 
Another common characterization method measures turbidity, where in 
the presence of DNA, the reaction appears cloudy and in the absence of DNA, 
the reaction appears clear (Figure 5). 39 The cloudiness is caused by the buildup 
of an amplification product, magnesium pyrophosphate. 
 
Figure 5: Turbidity characterization of LAMP products (adapted from Santos et al.). 
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Lastly, fluorescent dyes which bind to double stranded DNA (ds-DNA) can 
be used to characterize LAMP amplification. Positive amplification is represented 
by a color change and can be easily detected by eye or using UV light (Figure 6). 
40 However, the source of the amplification is unknown. In this study, there was a 
false positive in the sample without target DNA, but information is not known 
about what was amplified.  
 
Figure 6: Fluorescent dye characterization of LAMP products (adapted from Senarath et 
al.). 
These current methods are limited by the fact that they provide binary 
results. If there is amplification in the absence of DNA, it is not possible to 
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characterize the amplification in the presence of DNA because both results look 
the same, as shown in Figure 6. There are many examples in the literature of 
false positives in LAMP and how it is difficult to identify them using conventional 
methods like agarose gels. The yellow underlined samples in Figure 7 were false 
positives but appear as true positives with the agarose gel characterization 
method, which is problematic during assay development and usage. 41 
 
Figure 7: False positive results in LAMP (adapted from Suleman et al.). 
 
Restriction enzyme digests can be used to provide specificity results for 
LAMP reactions. Restriction enzymes recognize and cut specific DNA sequences 
and because LAMP amplicons are concatemers of products, this results in a set 
of products whose sizes can be predicted. Although this leads to fewer products 
to characterize, the readout can still be difficult to interpret on an agarose gel 
(Figure 8). 39  
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Figure 8: Restriction enzyme digest characterization of LAMP products (adapted form 
Santos et al.) 
  
During assay development, the samples in the absence of DNA have a 
higher likelihood to produce amplicons due to the inherent complexity of LAMP 
and unoptimized conditions, so more usable tools with simple readout are 
needed to characterize this nonspecific behavior. I sought to create a better tool 
using fluorescence imaging and acrylamide gels for higher resolution 
identification of digest products. 
 
Multiplexing LAMP and integration with a paper chip 
Multiplexed LAMP (mLAMP) assays exist, but not in a portable POC device 
format. In addition, most mLAMP assays are two LAMP assays in parallel with two 
separate reaction chambers. There is evidence in the literature suggesting multiple 
primer combinations in a single LAMP reaction are possible.42-45 In addition, there 
are several ways to multiplex lateral flow strips, our desired endpoint detection 
method. 46 
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Our lab and others have developed paper microfluidic platforms for nucleic 
acid amplification. 42-50 Many of these platforms involve isothermal amplification 
using LAMP, demonstrating its relevance and usefulness in a paper microfluidic 
platform. Hiltunen et al. developed a roll-to-roll processing system to generate 
high-volume production of PDMS-paper microfluidic devices, on the scale of tens 
of thousands of devices per hour, which can help lower costs for low-resource 
settings. However, the detection method was based on fluorescence and required 
several self-constructed equipment and laboratory equipment, which would not be 
possible to implement in LRS. Seok et al. adopted a paper-based 3D microfluidic 
approach to amplify multiple DNA targets, but similarly, readout was based on HNB 
fluorescence measured by a ChemiDoc imaging system (Biorad, Hercules, CA) 
that is not suitable for the point-of-care. 47 
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Chapter 2: Singleplex LAMP Development and Optimization for HPV16 and 
HPV18 
 
This chapter focuses on Aim 1 of my thesis work. The goal of this work was 
to develop and optimize two singleplex LAMP assays for HPV16 and HPV18 to 
amplify clinically relevant concentrations of DNA in 30 minutes or less. There are 
over 100 strains of HPV, and HPV16 and HPV18 are responsible for 70% of 
cervical cancers. Differential detection of the two subtypes is valuable because 
HPV16 has “preferential risk” for squamous cell carcinoma (SCC) while HPV18 
has increased risk for adenocarcinoma (AC). 14 AC has poorer prognosis than 
SCC, so detection is important to change clinical outcomes for patients. 15 The 
HPV18 LAMP assay was based on a previously published LAMP primer set 48, 
which we optimized for our target specifications. The HPV16 LAMP assay required 
de novo primer design, which enabled investigation of reaction kinetics and 
probing of specificity of the LAMP reaction.  
In addition, a new fluorescent imaging workflow was developed to take 
advantage of the functionalities afforded by loop primers and to investigate the 
relationship between what was visualized on gels and what was binding to the 
lateral flow strip. In conclusion, two singleplex LAMP assays were optimized for 
HPV16 and HPV18 LAMP and used as starting assays for subsequent 




LAMP suitability for low-resource settings  
There are several advantages of isothermal amplification methods 
compared to conventional PCR for low-resource settings. These include simple 
heating requirements (i.e. a water bath), short reaction times (15-90 min), and ease 
of operation. There are a wide array of isothermal amplification methods to choose 
from, differing in characteristics such as target template, operating time and 
temperature, steps in operation, and tolerance to crude samples.49 Loop-mediated 
amplification (LAMP) was chosen because the target was a HPV gene (DNA), the 
reaction time can be optimized to less than one hour, only one step and 
temperature are required, and the reaction can tolerate inhibitors found in crude 
samples, as would be found in cervical swab clinical samples. 
LAMP is an isothermal nucleic acid amplification technique that is an 
alternative to the gold standard polymerase chain reaction (PCR).36 The LAMP 
reaction uses Bst polymerase with strand displacement activity and four base 
primers – forward primer (F3), backward primer (B3), forward inner primer (FIP), 
and backward inner primer (BIP) –  to amplify specific regions on the target DNA 
to generate a stem loop “dumbbell” structure that serves as the starting template 
for exponential amplification. The six target regions enable LAMP to be highly 
specific, making LAMP advantageous over other isothermal amplification 
methods for DNA. The output of a LAMP reaction is amplicons of various lengths, 
as opposed to one amplicon in PCR. Two additional primers –  called loop 
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forward (LF) and loop backward (LB) - can be added to the four base primers to 
accelerate the LAMP reaction.  
Furthermore, no additional proteins are required beyond Bst polymerase, 
which is not the case for other isothermal amplification methods for DNA. Helicase-
dependent amplification (HDA) requires an additional DNA helicase to unwind the 
duplex DNA and single-stranded binding proteins to promote and stabilize duplex 
unwinding before the DNA polymerase starts amplification. In some cases, HDA 
also utilizes a restriction endonuclease to cleave the target region and facilitate 
helicase binding to the target DNA. 50,51 Strand displacement amplification (SDA) 
requires a restriction endonuclease for nicking and a strand-displacing DNA 
polymerase, as well as an additional initial heat denaturation step to separate the 
dsDNA before amplification. 52 Recombinase polymerase amplification (RPA) 
requires several proteins as well – DNA recombinase, a strand-displacing DNA 
polymerase, and DNA-binding proteins.53 
Ease of downstream detection and high tolerance to crude samples make 
LAMP ideal for our goal of testing clinical cervical swab samples in low-resource 
settings. The enzyme (Bst polymerase) used in LAMP is less sensitive to inhibitors 
that may exist in crude samples when compared to Taq polymerase and other 
enzymes used in amplification methods. LAMP can be performed with minimally 
processed samples, making it useful for field applications and clinical samples. 
This results in increased opportunities for translation into low-resource settings.  
Lastly, LAMP provides a convenient and simple way to incorporate tags to 
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the generated amplicons that can allow binding to a lateral flow strip (LFS) for 
visual detection after amplification. Tags can be added to the loop primers, which 
bind and extend only after the dumbbell structure is created, ensuring the reaction 
is specific. LFS provides a simple visual readout of red control and test lines that 
could be easily used and interpreted.  
 
Spurious template-free amplification in LAMP 
Spurious negative, or template-free, nonspecific amplification is a common 
problem in LAMP due to the high coverage afforded by the six primers used in the 
reaction. 54-57 The presence of six primers in one reaction mixture can generate 
primer interactions and self-priming, which can lead to undesirable false positives. 
Typically, this problem is circumvented by performing a restriction endonuclease 
digest that will reduce the smear of LAMP amplicons to a manageable number of 
distinct bands, as visualized through gel electrophoresis.  
Because the LAMP amplicons have LFS-specific tags, LFS can be run in 
addition to a restriction endonuclease digest gel to determine if the LAMP amplicon 
is specific. However, there exists a knowledge gap between the gel result and LFS 
result. To this end, I explored possibilities of connecting the two results directly. I 
developed a new characterization workflow to identify spurious template-free 
amplification that can be used to facilitate assay development and eliminate 
template-free amplification for more robust LAMP assays. 
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Characterization of LAMP specificity using loop primers 
Although LAMP has grown in use, characterization of LAMP assays during 
assay development is not straightforward and developers often rely on indirect 
evidence of specific amplification. In addition, the role of the loop primers has not 
been well-explored beyond reaction acceleration.37,58 Using the loop primers for 
additional readout capabilities could enhance the use of LAMP in field and 
research settings.  
Lateral flow strips (LFS) are a qualitative method of assay visualization 
that involves the emergence of red lines when there is positive amplification (test 
line) and flow (control line) via the tagging of analytes with gold nanoparticles. 
LFS are used in pregnancy tests and other point-of-care (POC) diagnostics for 
their rapid and intuitive visual readout.59, 60, 61  
Traditionally, positive amplification for LAMP is detected via agarose gel 
electrophoresis using a double-stranded DNA dye like SYBRGreen and ethidium 
bromide. The resulting image does not distinguish between nonspecific primer 
amplification and target-specific amplification. For POC use, intercalating dyes 
have been used in situ and real-time fluorescence increase is observed by eye or 
using a portable reader.62 However, in this embodiment, the user has no internal 
control to detect the presence and amount of non-specific amplification.  
 
New HPV16 LAMP primer design 
First, I optimized the HPV18 LAMP assay using primers from a previously 
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published set and several titration experiments of multiple reagents. When 
optimizing the HPV16 LAMP assay using the published primer set from Luo et 
al.63, frequent nonspecific amplification was observed (Figure 9). The NTC 
samples in the agarose gel were digested with pvuII and showed the same 
products as the products that are positive in a HPV16 reaction.  
 
Figure 9: Nonspecific amplification with Luo et al. primers for HPV16 LAMP. 
 
False positive results are problematic for a LAMP assay. Therefore, I 
designed five new primer sets for the E7 gene of HPV16 using Eiken’s 
PrimerExplorer software in an attempt to overcome the nonspecific amplification 
issue. The performance of the five sets was compared with the Luo set as a 
reference. HPV16 plasmid DNA was tested at 105 copies, a reasonable lower 
limit of detection for a clinical test.64  
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Adding fluorescent tags to loop primers 
I expanded loop primer functionality by adding a fluorescent tag, 6-FAM 
(fluorescein), to the HPV16 loop primers to enable downstream detection via two 
modalities: 1) amplicon binding to LFS containing an anti-FAM test line and 2) 
fluorescent detection of LAMP amplicons on a gel. By adding a fluorescent tag to 
the loop primers, the target amplicons will, in turn, contain the fluorescent tag 
after extension. The unstained agarose gel can be imaged with a filter specific to 
the fluorescent tag to screen out non-target amplification, thereby elucidating the 
target amplification of interest.   
This characterization strategy allowed exact determination of which 
products of the LAMP reaction led to positive test lines on the LFS. Optimizing for 
the amplification of these products has the potential to increase the sensitivity of 
the visual readout. LAMP often produces non-specific products that show up as 
false positives on gels, but as true negatives on LFS.  Recently, a similar strategy 
modifying loop primers was used to reduce false positives on LFS from 
nonspecific amplification.65  
As a test case for this enhanced characterization workflow, I expanded on 
our previously developed LAMP assay for the E7 gene of HPV16. HPV is the 
etiological agent of cervical cancer, which disproportionately affects women in 
low-resource settings who do not have access to effective screening methods.4 
HPV16 and HPV18 viral genomes encode the E6 and E7 oncogenes which 
produce proteins to initiate and maintain neoplastic growth of epithelial cells. The 
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E7 oncogene is activated early on in the HPV life cycle. Integration of the E7 
gene into the host genome has been associated with progression to invasive 
cancer11. E7 is the primary transforming protein that causes progression from 
precancer to cancer as the cancerous cells infect the epithelial layer. Detecting 
HPV DNA with a simple isothermal method such as LAMP that could be 
deployed in a POC diagnostic would address this unmet clinical need.  
 
2.2 Materials and Methods 
Generation of stock DNA 
Raw material (HPV16 and HPV18 plasmid DNA stocks) to be used for 
LAMP assay development and subsequently as assay standards was generated  
by cloning the E7 gene for HPV16 and HPV18 using the pGEM-T Easy Vector 
system (Promega, Madison, WI). The E7 gene was PCR-amplified from HeLa 
cell stocks purchased from Life Technologies (Grand Island, NY). The PCR 
protocol was adapted from the standard Taq Polymerase protocol of New 
England Biolabs (NEB, Ipswich, MA). The PCR product was purified via phenol 
chloroform extraction and ethanol precipitation to remove excess salts and 
primers from the PCR reaction. The cleaned PCR product was digested 
overnight with speI and aatII restriction endonucleases (NEB) to obtain sticky 
ends for cloning into the pGEM vector. The relevant band was gel-extracted and 
ligated to the pGEM vector and transformed into Top 10 cells (Life 
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Technologies). Plasmid DNA was extracted using a Mini Prep Kit (QIAGEN, 
Germantown, MD) and sequenced to confirm proper E7 DNA insert (GeneWiz, 
Cambridge, MA). After, a Midi Prep Kit (QIAGEN) was used to generate large-
scale plasmid DNA stocks. The stocks were linearized with zraI (NEB) to mimic 
HPV integrated into the host genome. Successful linearization was confirmed 
with agarose gel electrophoresis. The correctly sized fragment was gel-extracted 
using the QIAquick Extraction Kit (QIAGEN). Phenol chloroform extractions and 
ethanol precipitation were performed before the cloned DNA was stored in 1 mL 
aliquots at -20°C. 
 
Overall LAMP workflow 
The linearized plasmids were used as the HPV16 and HPV18 DNA 
standards for LAMP optimization and comparison to the PCR gold standard to 
make sure the reagents and conditions were working properly before testing 
DNA extracted from clinical cervical smear samples. The efficiency and 
specificity of the LAMP reaction were optimized by altering the concentration of 
primers, reagents (betaine, MgSO4, dNTPs), temperature, and reaction time. 
Dilutions of each reagent were tested to determine the optimal concentration for 
maximum amplification of HPV16 or HPV18 DNA.  
LAMP performance was evaluated in real-time with an EvaGreen 
intercalating dye (Biotium, Fremont, CA, USA). and a real-time instrument 
(Applied Biosystems, Foster City, CA, USA) using Quantstudio 5 software. 
 33 
Agarose gel electrophoresis was performed to obtain a qualitative measure of 
LAMP specificity. 2% agarose gels were run for 1 hour at 100V, and a 100 bp 
ladder (NEB) was used as a size marker. A positive LAMP reaction was indicated 
by the characteristic “ladder-like” smear of products while a negative LAMP 
reaction was indicated by no smear and the presence of only unextended primer 
bands.  
To characterize specificity, a restriction endonuclease digest was 
performed using enzymes that cut the LAMP amplicons to generate fragments 
with calculable sizes (pvuII for HPV16, blpI for HPV18) with the methods 
described in Notomi et al.36 Acrylamide gel electrophoresis was performed to 
obtain higher resolution visualization as opposed to the conventional agarose gel 
electrophoresis.  
 
Lateral flow readout of LAMP products 
Following the LAMP reaction, the amplified product was applied to a 
simple lateral flow strip (LFS) for visual detection and rapid readout of results. 
The LFS consists of a conjugate pad that contains streptavidin-coated beads, a 
detection zone with the control and test lines, and an absorbent waste pad. The 
HPV18 forward and backward loop primers were tagged with digoxigenin (DIG) 
and biotin, respectively, allowing these tags to be incorporated into the LAMP 
amplicons. The HPV18 LAMP amplicons bound to the streptavidin-coated beads 
via the biotin tag and aggregated at the anti-DIG test line, forming a visible line to 
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indicate a positive HPV18 LAMP reaction. The control line (anti-streptavidin) 
bound to excess streptavidin-coated beads, creating a visible positive control to 
show whether the lateral flow strip flowed properly. The HPV16 forward and 
backward loop primers were tagged with fluorescein (FAM) and biotin, 
respectively, allowing these tags to be incorporated into the HPV16 LAMP 
amplicons to bind the anti-FAM test line on the LFS. 
 
HPV18 singleplex LAMP optimization: MgSO4 optimization  
MgSO4 is a cofactor for Bst polymerase. Excess MgSO4 can stabilize ds-
DNA, making it difficult for Bst to strand displace. Two concentrations of MgSO4 
– 2 mM and 4 mM – were tested for positive amplification with priority given to a 
lower concentration. 2 mM MgSO4 is the amount of MgSO4 in the 10x isothermal 
amplification buffer, meaning there is no additional MgSO4 added to the reaction 
mixture. After LAMP, agarose gel electrophoresis was performed to visualize the 
reaction products to determine if amplification occurred. 
 
HPV18 singleplex LAMP optimization: Betaine optimization  
Betaine improves DNA amplification by reducing the formation of 
secondary structure in GC-rich regions. 66 Its role in amplification is similar to that 
of DMSO in PCR. 67,68 Three betaine concentrations – 0.3, 0.5 and 0.8 M – were 
tested with 2 mM MgSO4 to determine the optimum concentration of betaine for 
the HPV18 LAMP reaction and again, priority was given to a lower concentration. 
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After LAMP, the reaction products were visualized with agarose gel 
electrophoresis. 
  
HPV18 singleplex LAMP Lower limit of detection (LLOD) determination 
A range of HPV18 DNA concentrations from 107 to 102 copies were tested 
using the optimized LAMP conditions to determine the lowest copy number that 
could be amplified by the HPV18 LAMP assay. After LAMP, the products were 
run on an agarose gel for visualization of products.  
 
HPV18 singleplex LAMP LLOD in paper matrix and tube assay 
LAMP performance in the presence of a paper matrix was tested by 
applying DNA onto the polyethersulfone (PES) paper and inserting this paper, 
now containing DNA, into a tube of LAMP mastermix. These LAMP reactions 
were heated to 63°C and run alongside tube controls that did not contain PES. 
Afterwards, the reactions were run on a gel and lateral flow strips to determine if 
there was amplification. 
 
HPV16 singleplex LAMP development: primer design  
The four base primers (F3, B3, FIP, BIP) for HPV16 E7 were designed 
with PrimerExplorer software (Eiken, Tokyo, Japan) and the default parameters. 
The primers were synthesized by IDT (Integrated DNA Technologies [IDT], 
Coralville, IA, USA). A total of five four-primer sets were newly designed (Fig. 
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S1). HPV16 E7 gene plasmid DNA stocks for LAMP assay development were 
generated in-house as described previously.69 After a four-primer set was 
chosen, two additional loop primers – loop forward (LF) and loop backward (LB) 
– were designed and added to the reaction.  
 
HPV16 singleplex LAMP optimization: Primer set selection 
The four-primer sets were tested experimentally using LAMP reaction 
conditions adapted from Luo et al.63 LAMP was performed at 63°C for 60 minutes 
for all experiments. Real-time amplification was characterized with a real-time 
instrument (Applied Biosystems, Foster City, CA, USA) using Quantstudio 5 
software and EvaGreen intercalating dye (Biotium, Fremont, CA, USA). Endpoint 
amplification was characterized with agarose gel electrophoresis. 2% agarose 
gels loaded with the LAMP amplicons were run at 100 V for 1 hour. The four-
primer set with the fastest amplification time and absence of nonspecific 
amplification was selected for further optimization. After two loop primers were 
added, the six-primer set was optimized to minimize nonspecific amplification by 
titrating betaine (Sigma Aldrich, St. Louis, MO, USA) and MgSO4 (NEB) 
concentrations. 
 
HPV16 singleplex LAMP optimization: MgSO4 and Betaine optimization  
Three concentrations of MgSO4 – 2, 4, and 6 mM – were tested for 
positive amplification with priority given to a lower concentration. 2 mM MgSO4 is 
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the amount of MgSO4 in the 10x isothermal amplification buffer, meaning there is 
no additional MgSO4 added to the reaction mixture. Six betaine concentrations 
from 0 - 0.8 M were tested with 2 mM MgSO4. Agarose gels were run afterwards 
to determine if positive amplification had occurred. 
  
HPV16 singleplex LAMP Lower limit of detection (LLOD) determination 
The lower limit of detection of the optimized HPV16 LAMP assay was 
determined by testing serial dilutions of HPV16 plasmid DNA from 105 copies 
(cp) to 101 cp per reaction. Negative controls of 100 ng of Jurkat cell DNA and 
105 cp of HPV18 DNA, and a mixed sample of 105 cp of HPV16 and 105 cp of 
HPV18 DNA were performed to test for specificity and sensitivity.  
 
HPV16 singleplex LAMP LLOD probit analysis 
MATLAB (Mathworks, Natick, MA, USA) was used to statistically analyze 
the LLOD results from 9 replicates (3 experiments with 3 replicates per 
experiment). The probability of detection was calculated using probit analysis 
with a 95% cutoff.70 
 
HPV16 singleplex LAMP development: fluorescent loop primers 
Fluorescent tags enable downstream detection of the amplicons via LFS 
and fluorescent imaging (Figure 10). 
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Figure 10: Fluorescent tags enable detection via gel and LFS. 
 
An HPV16 LAMP amplicon must be tagged with FAM and biotin to appear 
on the LFS as a positive FAM test line. One end of the amplicon needs FAM to 
bind the anti-FAM test line while the other end needs biotin to bind streptavidin-
coated gold nanoparticles that produce red lines upon capture and aggregation. 
The anti-streptavidin control line binds excess nanoparticles and serves as a 
positive flow control. Fluorescent tags were added to the 3’ or 5’ end of the LF 
primer (Figure 11a) and biotin was added to the 3’ or 5’ end of the LB primer 
(Figure 11b). LB binds between the B1c and B2c regions while LF binds between 
the F2c and F1c regions. The primers were synthesized by IDT. Four 
experimental loop primer sets and two control loop primer sets were tested for 
amplification efficiency and the absence of nonspecific amplification (Table 1). 
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Figure 11: Schematic of the tag placement for HPV16 LF and LB primers. 
 
Table 1: Loop primer set compositions with 3' or 5' tags. 
Loop primer set Composition 
A No loop 
B Untagged loop 
C Probes (3’) 
D Primers (5’) 
E LF probe, LB primer 
F LF primer, LB  probe 
 
HPV16 singleplex LAMP development: loop primer and tag investigation 
Adding loop primers to the LAMP reaction can accelerate the reaction, 
making it more promising for POC applications where short reaction time is critical 
to return an answer to a patient in the same visit. 37 Loop primers with lateral flow 
strip tags are also how LAMP amplicons can be connected to the lateral flow strip. 
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Fluorescent tags were added to the 3’ or 5’ end of the loop forward (LF) primer 
sequence, while biotin tags were added to the 3’ or 5’ end of the loop backward 
(LB) primer sequence. Primers with tags on the 5’ end were able to extend because 
there was a free 3’ OH group available for amplification. Primers with tags on the 
3’ end were unable to extend because the 3’ OH group was capped with the tag.  
I examined the effects of making each loop primer – loop forward (LF) and 
loop backwards (LB) – a probe or a primer. Four combinations were tested and 
are summarized in the following table. Following the reaction, the amplified product 
was run on a gel and imaged using the FAM filter, as well as applied to a LFS for 
visible detection.  







1 Probe Probe 
2 Primer Primer 
3 Probe Primer 
4 Primer Probe 
 
Fluorescent Imaging 
Unstained agarose and acrylamide gels for HPV16 LAMP were imaged 
using the Typhoon Trio system (General Electric Healthcare, Pittsburgh, PA, 
USA). The fluorescence scan acquisition mode was used for the 520 BP 40 
emission filter. The PMT voltage and pixel size were set to 400 and 200, 
respectively. The sensitivity was set to Normal. Images were processed with 
ImageJ software (National Institutes of Health, Bethesda, MD, USA).  
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Fluorescent ladder generation 
A fluorescent FAM ladder (FL) to size the FAM digest bands was made in-
house by adding Klenow polymerase (NEB) and fluorescent dNTPs 
(JenaBioscience, Jena, Germany) to the mspI-digested pBR ladder (NEB). The 
reaction was performed at room temperature for 12 minutes. The DNA was 
purified using phenol-chloroform extraction and ethanol precipitation. Each band 
in the FL had four more bp than those in the unmodified mspI ladder. L = 
unmodified mspI digest of pBR ladder. FLC = fluorescent ladder control (created 
by previous Klenow experiment as positive control). F = FAM dCTP was added. 
K+ = Klenow added. K- = no Klenow added. 
 
Figure 12: Fluorescent FAM ladder generation. 
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HPV16 singleplex LAMP characterization: PvuII digests 
The HPV16 LAMP targets contained a restriction enzyme site for pvuII. 
pvuII (NEB) digests were performed at 37°C overnight. The digest products were 
run on a 12% acrylamide gel at 100 V for 2 hours. The unstained gel was imaged 
using the Typhoon Trio system.  Afterwards, the unstained gel was stained with 3 
µl of 10,000X SYBRGreen (Life Technologies, Carlsbad, CA, USA) and 30 ml of 
1x Tris/Borate/EDTA (TBE) buffer for 30 minutes on a rocking platform. The 
stained gel was imaged using the Typhoon Trio System. 
 
Lateral Flow Strip (LFS) operation and imaging 
Lateral flow strips were purchased from Bio-UStar Technologies 
(Hangzhou, China). 5 µl of each completed LAMP reaction was added to the 
sample pad, followed by 60 µl of water as running buffer. Results were visible in 
5 minutes. The strips were imaged after 10 minutes using a Nikon SMZ18 
stereomicroscope (Nikon, Tokyo, Japan) at 0.75x magnification. 
 
HPV16 singleplex LAMP characterization: LFS Extraction 
LFS were run and dried at room temperature for 10 minutes before 
imaging as described above. Images were taken before and after the test line 
was cut out.  All equipment was cleaned with DNA Away (Thermo Fisher 
Scientific, Waltham, MA, USA) between strips. The paper with the cut-out test 
line was placed into 50 ml of 1x Phosphate-Buffered Saline (PBS) and dialyzed 
 43 
for 1 hour at 4°C on a rotating apparatus. The PBS was removed and fresh PBS 
was added for another hour of washing to remove non-specifically bound 
products.  
After washing, the paper was added to a PCR tube with 75 µl of Elution 
Buffer (QIAGEN) and heated for 10 minutes at 95°C to elute the bound DNA. The 
paper was removed and the eluted DNA was purified using isopropanol 
precipitation. DNA concentration and purity were measured using the Nanodrop 
2000 spectrophotometer (Thermo Fisher Scientific). 
 
HPV16 singleplex LAMP characterization: Denaturing gel electrophoresis 
To eliminate secondary structure interactions, pvuII-digested samples 
were loaded on a 10% polyacrylamide gel with urea and run at 70 W for 2 hours. 
The unstained gel was imaged and subsequently stained with 15 µl 1x SybrGold 
(Life Technologies) and 250 ml 1x TBE buffer for 30 minutes on a rocking 
platform. The stained gel was then imaged for fluorescence with the Typhoon 
system as previously described. 
 
2.3 Results and Discussion 




Table 3: List of final HPV16 and HPV18 LAMP primers used. 














HPV18 LAMP Assay Optimization: MgSO4 optimization 
Agarose gels were run to determine the presence of amplification for the 
HPV18 LAMP reaction (Figure 13). A positive LAMP reaction is indicated by a 
ladder-like smear of different product sizes. 2 mM MgSO4 was the ideal condition 
for the LAMP reaction to amplify with the probe-tagged loop primers. 2 mM 
MgSO4 was the amount of MgSO4 in the 10x isothermal amplification buffer, 
meaning there was no additional MgSO4 added to the reaction mixture. The 
LAMP reaction for tagged primers did not amplify in any other MgSO4 
concentration. In contrast, the LAMP reactions with no probe- labeled primers 
(nP) all amplified. There was a different ladder-like smear because the probes or 
tags can increase the molecular weight of the amplicons. Adding probes to the 
loop primers may inhibit amplification because the DIG and biotin can increase 
steric hindrance for primers and Bst to bind. The lack of amplification in the 




Figure 13: Agarose gel results for HPV18 LAMP MgSO4 optimization. 
 
HPV18 LAMP Assay Optimization: Betaine optimization 
For assay optimization and troubleshooting, real-time amplification data can 
be more useful than the gel data because real-time data can show the difference 
in time for each reaction, as opposed to an endpoint result. The y axis corresponds 
to the amount of amplification as measured by fluorescence and the x axis 
corresponds to time in minutes. As shown in Figure 14, for the LAMP reaction 
without tag/probe-labelled loop primers, 0.3 M (cyan blue line) amplified the 
fastest. For the LAMP reaction with probe-labeled primers, there was not much 
difference between the three betaine concentrations (0.3, 0.5, 0.8 M). The betaine 
concentration with the most consistent results was 0.5 M. A higher betaine 
concentration of 0.8 M had comparable amplification and a lower betaine 
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concentration generated less reproducible amplification. The no template controls 
did not generate any amplification curves, as expected. 
 
 
Figure 14: Amplification curves for HPV18 LAMP betaine optimization. 
 
HPV18 singleplex LAMP optimization: 30 minutes reaction time 
dNTPs concentrations were titrated along with betaine concentrations to 
examine amplification potential in 30 minutes. 0.5M betaine, 0.8 mM dNTPs, 2 mM 
MgSO4 was chosen as the optimal condition for amplification because this 




Figure 15: dNTP and betaine optimization for HPV18 LAMP in 30 minutes. 
 
HPV18 singleplex LAMP LLOD in tube assay 
The in-tube reaction for HPV18 LAMP was carried out in a final volume of 
25 µl with 1 µl of the DNA sample, 10x Isothermal Amplification Buffer (New 
England Biolabs), 8 U Bst 2.0 DNA polymerase, 0.8 mM dNTPs, 0.5 M betaine, 5 
pmol each of HPV18 forward and reverse primers (F3 and B3), 40 pmol each of 
HPV18 forward and reverse inner primers (FIP and BIP), and 20 pmol each of 
HPV18 forward and reverse loop primers (LF and LB).  
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HPV18 singleplex LAMP LLOD in paper matrix and tube assay 
The LLOD of LAMP in paper was 103 copies, which was the same as the 
LLOD in tube (Figure 16). This was close to the clinically relevant LLOD of ~1000 
copies/sample, as calculated by using average HPV18 copies and amount of 
cellular DNA per sample from Swan et al.64 
 




HPV16 LAMP Assay Development and Optimization 
Isothermal nucleic acid amplification assays are quantified using “time to 
amplification” in real-time amplification instruments. “Time to amplification” is 
defined as the time at which the fluorescence signal – which is related to DNA 
amplification – exceeds the threshold background fluorescence. Here, time to 
amplification in minutes was used.  
Positive amplification on an agarose gel for LAMP is defined as the 
presence of a ladder-like smear of products. From the agarose gels (Figure 17), 
Set 1 had weak amplification for 107 cp and no amplification for 105 cp. Set 5 had 
strong amplification for 107 cp, but variable amplification for 105 cp. Set 4 showed 
nonspecific amplification. For these reasons, Sets 1, 4, and 5 were excluded 
from further testing. Sets 2 and 3 did not exhibit nonspecific amplification and 
had strong amplification for 107 cp and 105 cp, so real-time amplification kinetics 
were used to further compare the two primer sets. Both sets had similar 
threshold times for 105 cp (42 and 45 minutes for Sets 2 and 3, respectively), but 




Figure 17: Agarose gel results for new HPV16 primer sets. 
 
The Set 2 primers were selected for subsequent assay optimization by 
titrating betaine and dNTP concentrations (Figure 18). The sequences for the Set 
2 primers are in Table 4. 2 mM MgSO4 and 0.3 M betaine were the optimal 
conditions for positive and consistent amplification among triplicates. The 





Figure 18: Magnesium and betaine optimization for HPV16 LAMP with Set 2 primers. 
 
 Table 4: Newly-designed HPV16 Set 2 primer sequences. 





LF ACAGTAGAGATCAGTTGTC  
LB GCCCATTACAATATTGTAACC  
 
Fluorescently-tagged HPV16 Loop Primers for LFS Detection 
After the four base primers were chosen, loop primers were designed to 
accelerate the reaction. Fluorescent tags were added to the 3’ or 5’ end of the 
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loop forward (LF) primer sequence, while biotin tags were added to the 3’ or 5’ 
end of the loop backward (LB) primer sequence. Primers with tags on the 5’ end 
were able to extend because there was a free 3’ OH group available for 
amplification. Primers with tags on the 3’ end were unable to extend because the 
3’ OH group was capped with the tag (Figure 11), thereby creating a probe with 
the sequence that could simply bind but not integrate with the product. Six loop 
primer sets (Table 1) were tested with the optimized LAMP recipe (Figure 18) 
and run on lateral flow strips. Only the loop primer sets with a FAM-tagged LF 
(Loop primer sets C-F) generated a positive FAM result on the LFS, 
demonstrating additional functionality for the LAMP amplicons (Figure 19). 
Conversely, there were no positive LFS results for the no template control (NTC) 
samples. 
Different times to amplification were observed for each loop primer set. 
LAMP proceeded twice as quickly with untagged loop primers (Loop primer set 
B, 13 minutes) than with no loop primers (Loop primer set A, 28 minutes), 
underscoring the value of loop primers in accelerating LAMP. Loop primer sets 
C-F with tagged loop primers amplified between 14-27 minutes. These increases 
in amplification time compared to untagged loop primers could be due to steric 
hindrance of the tags, which could make it harder for the Bst polymerase to 
access the target DNA for amplification.  
However, these times (14-27 minutes) were sufficient for POC diagnostic 
applications. Loop primer sets D (14 minutes) and F (18 minutes), where LF-FAM 
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behaved as a primer, had the shortest amplification times. Of Loop primer sets 
C-F, Loop primer set C was the least efficient because there were only 4 primers, 
making it comparable to loop primer set A that had no loop primers. Loop primer 
set D was the most efficient because LF and LB retained their primer 
characteristics with tags on the 5’ end, enabling amplification with 6 primers. 
Loop primer set E was slower than Loop primer set F, suggesting the LB primer 
was slower to amplify than the LF primer. These amplification results were 
supported by the gel results and offer quantitative values to amplification 
efficiency. Loop primer set D was chosen as the optimal set for rapid 
amplification with FAM functionality. 
 
 
Figure 19: Testing the role of loop primer tag placement on amplification. 
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HPV16 digest gel fluorescent imaging  
After LAMP, the samples from Figure 19 were digested overnight with 
pvuII. 12% polyacrylamide gel electrophoresis was performed to obtain higher 
resolution imaging of the digest bands. Different loop primer sets yielded different 
FAM-labelled digest products. Loop primer sets D and F had more FAM-labelled 
digest bands than Loop primer sets C and E (Figure 21), indicating that more 
products were formed, likely explaining the faster time to amplification for these 
conditions. However, after SYBRGreen staining (Figure 21b), the additional FAM 
bands of Loop primer sets D and F were less visible because of the presence of 
non-FAM-labelled bands. This result highlights the value of the FAM digest gel, 
as the FAM-labelled products are what can bind to the FAM test line of the LFS 
and the non-FAM-labelled products are not useful for LFS readout.  
Denaturing polyacrylamide gel electrophoresis was performed on the 
HPV16 LAMP products to eliminate potential secondary structure interactions by 
denaturing double-stranded DNA (ds-DNA) to single-stranded DNA (ss-DNA) 
(Figure 21c). Conditions with tagged probes (Loop primer sets C and E) were 
hypothesized to dissociate because they could not extend and thus could only 
bind to the product. The result after denaturing these products is 2 products, one 
smaller sized FAM product and one larger sized non-fluorescent product (Figure 
20, left). Because tagged primers can extend, the denatured products for these 
conditions (Loop primer sets D and F) were expected to contain fluorescence 
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(Figure 20, right). The FAM tag could be integrated into variously sized products 
depending on when amplification ended.  
 
Figure 20: Probe and primer hypothesis with the denaturing gel. 
 
This hypothesis was supported by the fluorescent gel results. Loop primer 
sets D and F showed FAM-labelled bands because these sets contained FAM 
primers, demonstrating FAM integration into the amplicons. Loop primer sets C 
and E did not show FAM-labelled bands because the FAM probes were unable to 
integrate into the amplicons and dissociated upon denaturation. The FAM tag 
was unbound and existed as one size (<30 bp) for Loop primer sets C and E 
because the LF primer sequence could not amplify as a primer. The FAM tag 
was integrated with amplicons of various sizes in Loop primer sets D and F 
because the LF primer sequence could amplify as a primer. Loop primer sets A 
and B were negative control reactions that contained no FAM primers or 
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probes.  After SYBRGold staining for ss-DNA, the same smear of products was 
imaged for all Loop primer sets (Figure 21d), losing the FAM-specific information 
from the unstained gel. Again, this is a limitation of non-specific conventional 





Figure 21: Acrylamide gel results of HPV16 LAMP pvuII digests with a FAM filter. 
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LFS elution of pvuII-digested products 
The pvuII-digested products from the anti-FAM test line on the LFS were 
eluted to confirm the presence of FAM in the products. After DNA purification and 
acrylamide gel electrophoresis, the eluted products showed the same unstained 
FAM-labelled band and SYBRGreen-stained band patterns as those of the pre-
LFS products in Figure 21a (Figure 22). Therefore, the three FAM bands that 
were previously imaged and characterized were the products that bound to the 
LFS and led to a positive test line result. This demonstrated that what was 




Figure 22: Acrylamide gel results of LFS-extracted and non-LFS-extracted pvuII-
digested products. 
 
HPV16 LLOD Determination 
The in-tube reaction for HPV16 LAMP was carried out in a final volume of 
25 µl with 1 µl of the DNA sample, 10x Isothermal Amplification Buffer (New 
England Biolabs), 8 U Bst 2.0 DNA polymerase, 1 mM dNTPs, 0.8 M betaine, 5 
pmol each of HPV16 forward and reverse primers (F3 and B3), 40 pmol each of 
HPV16 forward and reverse inner primers (FIP and BIP), and 20 pmol each of 
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HPV16 forward and reverse loop primers (LF and LB). Lower limit of detection 
(LLOD) analysis was performed for HPV16 LAMP optimized with Set 2 primers 
and Loop primer set D. Three LLOD experiments testing serial dilutions of 
HPV16 plasmid DNA from 105 cp to 101 cp were performed. 
There was a case of spurious nonspecific amplification on the SybrGreen-
stained acrylamide gel (Figure 23b, NTC sample), but the FAM-labelled digest 
gel (Figure 23a) did not show the three-band pattern characteristic of a positive 
HPV16 sample. Therefore, the NTC sample was judged a negative result. This 
was confirmed by a negative LFS result (Figure 23c), demonstrating the FAM 
digest gel was predictive in linking the gel result to the LFS, while the agarose gel 
was inconclusive. This would have been judged a false positive result in the 
conventional characterization workflow that only includes imaging of dsDNA 
products on agarose gels.  
The positive amplification results from all three experiments were inputted 
into the MATLAB probit analysis to generate a probability of detection plot 
(Figure 23d). The LLOD with 95% detection probability was 104.5 or 31,622 
copies/reaction, which is close to the clinically relevant concentration of 104 
copies by Swan et al. 64 The agarose gel results for one LLOD experiment are 





Figure 23: HPV16 LAMP LLOD with Loop primer set 4.   
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 In this work, I optimized two singleplex HPV16 and HPV18 LAMP tube 
assays to amplify in 30 minutes. The lower limits of detection were within the 
clinically relevant range of DNA copy number, with 104 and 103 cp for HPV16 and 
HPV18 LAMP, respectively. Optimization was performed by titrating betaine, 
dNTPs, and MgSO4 concentrations. All experiments were performed with a 25 ul 
reaction volume. In order to combine the two assays into one assay for 
multiplexing in Aim 2, the reaction volume will be halved for both assays to 12.5 
ul to maintain a total reaction volume of 25 ul. 
 The HPV18 LAMP primers were taken from a previously published primer 
set, but the HPV16 LAMP primers were designed in-house. Starting from the new 
primers allowed us to develop a new characterization workflow to assess and 
monitor the LAMP assay performance. I showed that for HPV16 LAMP, FAM-
labelled gels can be used to establish specificity of LAMP results on LFS. 
Fluorescently imaging unstained gels with an LFS tag-specific filter ensures the 
visualized bands can bind to the LFS. Utilizing fluorescent imaging with a 
restriction enzyme digest to reduce the number of amplicon sizes in LAMP 
generates a simplified depiction of a complex reaction that can be further 
investigated. 6-FAM tags were added to different ends of a LAMP loop primer 
sequence, and I hypothesized that adding FAM to the 5' end of the sequence 
generated a primer so FAM could be integrated into amplicons. On the other 
hand, adding FAM to the 3' end resulted in a probe, which could not integrate into 
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amplicons during amplification and instead, only bound to its complementary 
sequence after amplification.  
FAM-labelled digest band patterns differed depending on where the 6-
FAM tag was added. The tag was added to the 3’ end for Loop primer sets C and 
E, and the 5’ end for Loop primer sets D and F. Loop primer sets D and F had 
more FAM-labelled products because the LF primer enabled more amplification 
with more initiation sites. Positive LFS results were generated from all four Loop 
primer sets that had FAM (Loop primer sets C-F). This work shows that adding 
the 6-FAM tag to the 5’ or 3’ end can alter the kinetics of product formation during 
amplification. Consideration should be taken to add tags (FAM, digoxigenin, Cy5, 
etc) to the appropriate end of the primer sequence to achieve the desired 
reaction time and product formation. 
Restriction enzyme-digested samples have fewer bands than the 
undigested LAMP-amplified samples, making them more straightforward to 
correlate to the LFS. Imaging FAM bands in the fluorescent imaging workflow as 
opposed to all the bands in the conventional imaging workflow selects for bands 
that can bind the FAM test line on the LFS, the chosen method of POC visual 
readout. This method of fluorescently imaging post-digest bands allows 
amplification verification by revealing LAMP's characteristic multiple bands in the 
pre-digest, while allowing for specificity analysis by revealing the characteristic 
band pattern present in the post-digest product. This workflow will reduce time 
spent troubleshooting and help assay developers avoid nonspecific amplification 
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in isothermal protocols that was previously difficult to detect. However, a 
restriction site must be present in the target as a design requirement for this 
strategy. Most importantly, fluorescent imaging can screen out false positives 
often seen (and often undetected) on gels due to primer interactions, a common 
problem for LAMP due to the numerous primers.71, 72 
Loop primers can have additional functionality beyond accelerating the 
LAMP reaction. Fluorescent tags can be added to loop primers to enable lateral 
flow strip detection and fluorescent imaging, and these results can be linked to 
elucidate products binding to the LFS. In this work, specific band patterns on the 
FAM digest gel were identified that corresponded to a positive LFS result.  
Denaturing gel electrophoresis was run to eliminate potential effects of 
secondary structure and confirmed my hypothesis that when the 6-FAM tag was 
added to the 3’ end, the primer sequence acted as a probe and did not integrate 
into the LAMP amplicons. However, when the 6-FAM tag was added to the 5’ 
end, the primer sequence was integrated into the LAMP amplicons. LFS elution 
was performed to characterize products bound on the strip directly. These 
products matched those of the post-digest products, confirming that the sample 
loaded on the LFS is sufficiently captured and FAM-specific.  
In summary, I developed a sensitive and specific LAMP assay to detect HPV16 
on a lateral flow strip as well as a simple method to determine if amplification was 
target-specific by using fluorescent probes and a fluorescent gel imager (Figure 
25). Positive amplification for LAMP is typically confirmed with agarose gel 
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electrophoresis and a restriction enzyme digest. 73,74-77 However, agarose gels do 
not provide information on whether the tag was incorporated during LAMP. This 
new fluorescent imaging strategy can elucidate what LAMP products bind to the 
LFS by selectively imaging for FAM-specific bands that can bind to the LFS. 
Additionally, acrylamide gels provide higher resolution of digest products. This 
workflow simplifies complex LAMP smears to a distinct band pattern that 
correlates to a positive LFS result. It allows the assay developer to look for the 
needle in the haystack to more easily characterize LAMP amplification.  
 
Figure 25: Novel fluorescent imaging workflow to connect gel results with LFS results. 
 
Lastly, distinct fluorescent tags can be added to LAMP assays to develop 
assays where two or more targets need to be detected simultaneously, and this 
strategy was utilized in Aim 2 when multiplexing HPV16 and HPV18 singleplex 
LAMP into one multiplexed LAMP (mLAMP) assay. Being able to distinguish 
which target is being amplified using fluorescence enables more reliable 
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identification and optimization of amplification. This development tool would be 
used during assay development and not in the final assay, which would have 
additional design and operating constraints. Ultimately, this workflow will facilitate 
characterization and quality assessment for nucleic acid amplification assays in 
limited-resource settings.  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Chapter 3: Multiplexed LAMP (mLAMP) Development 
 
This chapter focuses on Aim 2 of my thesis work. The goal of this work 
was to combine the two optimized singleplex LAMP assays for HPV16 and 
HPV18 from Aim 1 into one reaction while retaining each respective assay’s 
lower limit of detection (LLOD) and specificity (Figure 25). For HPV16 LAMP, this 
was 104.5 copies and for HPV18 LAMP, this was 103 copies.  
 
Figure 26: Schematic of multiplex LAMP readout on LFS. 
 
Sequencing of the digest bands was performed for each HPV assay to 
determine specificity of the reaction using an orthogonal approach from the 
fluorescent imaging workflow. mLAMP was successfully achieved and confirmed 
using conventional methods as well as less conventional methods such as 
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sequencing LAMP products post-digest and the new fluorescent imaging assay 
described in Aim 1.  
Chip parameters were optimized for the mLAMP reaction and tested using 
the cloned DNA stocks. After the mLAMP reaction was thoroughly characterized 
and confirmed to be specific, the reaction was tested with several chip 
configurations in Aim 3 (Chapters 4 and 5).  
 
3.1  Significance 
Innovation of multiplexing LAMP assays 
Combining a multiplexed assay in a paper integrated device platform has 
not yet been demonstrated in the literature.  Multiplexed LAMP (mLAMP) assays 
exist, but not in a portable point-of-care (POC) device format. In addition, most 
mLAMP assays are two LAMP assays in parallel, with two separate reaction 
chambers. Each singleplex LAMP reaction contains 4-6 primers, so multiplexing 
another singleplex LAMP assay into the same tube reaction can generate a total 
of 10-12 primers, leading to many opportunities for nonspecific primer 
interactions that can complicate the reaction and lead to false positives. For 
effective and streamlined assay development, mLAMP assay characterization 
techniques are needed to properly identify these primer interactions and to 
distinguish nonspecific amplification from specific amplification. mLAMP assay 
optimization requires extensive titration testing of reagents to eliminate the many 
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potential nonspecific primer interactions that may occur and of other variables 
such reaction volume, reaction time, and reaction temperature. To this end, I 
developed a new fluorescent imaging workflow in Aim 1 to ascertain the sources 
of specific amplification in a LAMP reaction. 
Although limited, there is evidence in the literature suggesting that multiple 
primer combinations in a single LAMP reaction is possible. 42-45 Despite the 
challenges of mLAMP development and optimization, there have been some 
attempts to multiplex two LAMP reactions into one. These groups typically halved 
the LAMP reaction of each singleplex reaction and combined the two reactions 
together in one tube. 
Currently, the large majority of mLAMP assays are for food security and 
plant diseases, not for human health. My work to multiplex HPV16 and HPV18 
would be one of the few applications in human health for mLAMP. Shao et al. 78 
developed a mLAMP assay that could detect Salmonella spp (species) and 
Shigella spp in milk. The singleplex LAMP assays were developed separately 
and specificity was shown when non-target organisms were used as the template 
DNA and did not amplify in the LAMP reaction. For the mLAMP assay, specificity 
was	shown with a restriction enzyme digest that distinguished Salmonella from 
Shigella by looking at the different characteristic digest products. Lane 1 was 
Salmonella typhimurium, Lane 2 was Shigella flexneri, and Lane 3 was 
Salmonella and Shigella. LAMP products from Salmonella that were cut with the 
restriction enzyme HpaII had fragments that were ~50 bp while LAMP products 
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from Shigella that were digested were 200 bp (Figure 27). Therefore, the type of 
bacterial pathogen could be determined by the size of these different fragments. I 
incorporated this approach using restriction digests to determine the specificity of 
our multiplexed HPV16 and HPV18 LAMP assay.  
 
Figure 27: Multiplexed LAMP products after hpaII digest (Shao et al). 
 
Tomlinson et al. 45 developed a mLAMP assay that consisted of two 
reaction chambers for lateral flow detection of Phytophthora ramorum and 
Phytophthora kernoviae, two plant pathogens that affect oak and beech trees, 
respectively. Identification of Phytophthora species was important because 
treatment can be species-specific. In this study, DNA extraction, amplification 
and detection were performed separately but all on paper substrates. DNA 
extraction was done using a lateral flow device (LFD). The plant material was 
homogenized with beads and incubated in an extraction buffer before flowing on 
the LFD. The LFD membrane containing the DNA was directly put into the LAMP 
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reaction mix. Like our HPV18 LAMP reaction, their LAMP reaction contained 
biotin and DIG-labeled primers to allow binding to a LFD for detection. The LAMP 
amplicons were pipetted onto a detection LFD that generated a visible readout 
for the Phytophthora species present. This example further suggests, along with 
the work done in our lab, that it is possible to do all of these steps on paper and 
thus, on an integrated device. In addition, two reaction chambers can be used as 
an alternative approach if it is too difficult to conduct a single LAMP assay with 
12 primers.  
 
Relevance of mLAMP for HPV16 and HPV18 
To develop a self-contained diagnostic chip for cervical cancer screening, 
we must be able to simultaneously screen for the two most common subtypes 
that cause 70% of cervical cancer, HPV16 and HPV18, in a single combined 
reaction. Differential detection of the two subtypes is valuable because HPV16 
has “preferential risk” for squamous cell carcinoma (SCC) while HPV18 has 
increased risk for adenocarcinoma (AC). 14 AC has poorer prognosis than SCC, 
so it is important to detect it. 15 Furthermore, the ability to distinguish between the 
two genotypes enables epidemiological investigations that may help control 
possible epidemics in any given population.  
There is no mLAMP assay to date for HPV genotypes. A multiplexed 
LAMP (mLAMP) for two targets is a complex reaction involving 12 primers that 
has not been extensively characterized, unlike singleplex LAMP. To this end, I 
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sought to develop a multiplex LAMP (mLAMP) assay for the combined detection 
and differentiation of HPV16 and HPV18 in a single reaction on the same 





3.2  Materials and Methods 
Lateral flow differential detection enabled by tags  
 As described in Chapter 2, tags were added to each singleplex reaction to 
differentiate HPV16 and HPV18. This allowed the amplified products to be flowed 
through a LFS with test lines for both HPV types. For multiplexed detection of 
HPV16 and HPV18, the LFS needed three lines: an HPV16 test line, an HPV18 
test line, and a control line to ensure proper flow occurred. The HPV16 and 
HPV18 subtypes needed to be tagged with biotin to bind the streptavidin-
conjugate beads in the conjugate pad, as well as with distinct probes to be 
captured by two distinct test lines. To this end, the HPV16 forward and reverse 
loop primers were tagged with FAM and biotin, respectively, and the HPV18 
forward and reverse loop primers were tagged with DIG and biotin, respectively. 
The LFS had 3 lines (anti-FAM test line, anti-DIG test line, and anti-streptavidin 
control line) and were purchased from BioUStar Technologies (Hangzhou, 
China). 
Using this setup (Figure 28), if a patient were positive for HPV16 and 
HPV18 DNA, all 3 lines would appear – the FAM test line for HPV16, the DIG test 
line for HPV18, and the control line to ensure proper flow. If a patient were 
HPV16-positive only, the FAM test line and control line would appear. If a patient 
were HPV18-positive, the DIG test line and the control line would appear. If the 
patient did not have HPV16 or HPV18 DNA, only the control line would appear. 
There are two instances when results can be confounded. First, if there is 
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improper or no flow, the conjugate pad stays red and there are no lines shown 
after the run. This is very rare and was never observed in my experiments. 
Second, when there is excess tagged DNA due to amplification with a high input 
DNA copy number, there may not be any excess streptavidin beads to bind the 
control line. This is called the Hook effect, and it was observed for some of our 
samples in the singleplex reactions. The way to circumvent this is to operate 
below the high input DNA copy number that generates this result to ensure 
excess streptavidin beads are present or to create more sensitive lateral flow 
strips that have a higher number of streptavidin beads to start with. 
 
 
Figure 28: Multiplexed Lateral Flow Strip schematic for HPV16 and HPV18. 
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Sequencing pvuII digest bands of HPV16 singleplex LAMP 
For HPV16 LAMP sequencing, a blunt-end cloning strategy was utilized 
(Figure 29). PvuII digest bands were extracted from acrylamide gels using a Gel 
Extraction Kit (QIAGEN) and cloned into the zraI-digested pGEM vector 
(Promega, Madison, WI, USA). The plasmid backbone and purified digest band 
were ligated overnight and transformed into Top10 cells (Invitrogen, Waltham, 
MA, USA). Colony PCR was performed to select colonies with positive 
transformations. Liquid cultures of the positive colonies were grown, processed 
with a MiniPrep Kit (QIAGEN), and sequenced (Genewiz Sequencing, 
Cambridge, MA, USA).  
 
Figure 29: HPV16 cloning strategy for sequencing. 
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Sequencing blpI digest bands for HPV18 singleplex LAMP 
For HPV18 LAMP sequencing, a cohesive-end cloning strategy was used. 
BlpI digest bands were gel-extracted and cloned into the blpI-digested pET-Duet 
1 vector. The digest band insert and respective plasmid were ligated overnight 
and transformed into Top10 cells. Several ligation conditions such as insert: 
plasmid ratio, temperature, and time were tested to obtain positive ligation. 
Colonies expressing the cloned vector were screened with colony PCR and the 
positive inserts were grown, Miniprepped, and sequenced to ensure that the 
digest bands were as calculated, confirming the specificity of the two singleplex 
assays.  
 
mLAMP development and optimization 
All 12 primers (six each for HPV16 and HPV18 LAMP) were combined into 
one reaction mixture and optimal assay conditions for the amplification of both 
targets simultaneously were identified through iterative titrations of different 
assay reagents including the primers themselves. The optimized conditions for 
HPV16 and HPV18 singleplex LAMP in tube from Aim 1 were used as a starting 
point. I halved the volumes of each reaction to retain a 25 µl volume and found 
that the two LAMP reactions were compatible with each other. The optimization 
focused on reducing the HPV16 and HPV18 LAMP assay times to 30 minutes 
without compromising amplification efficiency. Different ratios of HPV16:18 
primers and different reaction times were tested. Jurkat cell DNA was used as a 
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genomic DNA negative control that should not amplify under LAMP conditions. 
 
Using fluorescent imaging to test and optimize mLAMP 
The new fluorescence assay developed in Aim 1 was used to identify 
which bands bind to the LFS and to further demonstrate the specificity of the 
mLAMP reaction. mLAMP was performed with fluorescent probes to differentiate 
HPV16 LAMP products from HPV18 LAMP products. HPV16 LAMP amplicons 
were tagged with FAM and HPV18 LAMP amplicons were tagged with a 1:1 
mixture of Texas Red for fluorescent imaging and DIG for lateral flow strip 
detection. Using the fluorescent assay, the gels now contained fluorescent 
information about what type of HPV was present after LAMP. HPV16 products 
appeared only with the FAM filter, while HPV18 products appeared only with the 
Texas Red filter. The merged image was constructed with ImageJ and the color 
corresponded to each HPV type. 
 
3.3 Results and Discussion 
Sequencing HPV16 digest bands 
Three pvuII digest bands (Figure 30) were extracted from acrylamide gels 
and cloned for sequencing. The sequences of the cloned bands were analyzed 
for the presence of LAMP primer segments as well as non-primer target regions 
to distinguish amplicons from products generated by self-priming. I took an 
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orthogonal approach from fluorescent imaging to confirm specificity by 
sequencing the nonfluorescent bands. LAMP products are rarely sequenced 
because of difficulty isolating the bands, but the fluorescent workflow reduces 
them to a manageable few. Bands 2 and 3 were successfully sequenced and 
matched predicted digested products (Figure 31). This demonstrates LAMP 
reaction specificity via sequencing of digest bands, which is simpler to implement 
than previous methods that sequenced undigested LAMP amplicons and often 
involved specialized equipment.14,79,80 Band 1 was unable to be sequenced, 
potentially because it contained more than one digest product.  
 




Figure 31: Sequencing results for HPV16 LAMP digest products. 
 
Sequencing HPV18 digest bands 
Two blpI digest bands (Figure 32) were extracted from acrylamide gels 
and cloned for sequencing. The sequences of the cloned bands were analyzed 
for the presence of LAMP primer segments as well as non-primer target regions 
to distinguish amplicons from products generated by self-priming. Both bands 
were successfully sequenced and matched predicted digested products (Figure 
33). As with the HPV16 sequencing results, these results demonstrate HPV18 
LAMP reaction specificity via sequencing of its digest bands. The sequencing 
results of HPV16 LAMP and HPV18 LAMP digest products indicate that the 
singleplex reactions are specific and can be combined to create a multiplexed 
HPV16 and HPV18 LAMP reaction. 
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Figure 33: Sequencing results for HPV18 LAMP digest products. 
 
mLAMP optimization with fluorescent imaging workflow 
 The fluorescent workflow was used to characterize the efficiency of 
mLAMP as different conditions were tested. The HPV16 and HPV18 mLAMP 
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assay was performed alongside two control assays of the singleplex HPV16 and 
HPV18 assays. The samples tested were NTC, Jurkat DNA, 16, 18, and 16+18 
DNA at various input copy numbers. If there was inconsistent amplification in the 
singleplex control assays, then that could be the reason for inconsistent 
amplification in the mLAMP. This allowed us to pinpoint the problem to the 
singleplex assay as opposed to the combined multiplex assay. Afterwards, action 
could be taken to address the problems of the singleplex and to alter reagent 
concentrations to solve the problem.  
In the following example (Figure 34), only HPV16 LAMP amplicons are 
expected to appear under the FAM filter. For the mLAMP and HPV16 LAMP 
assays, this means all samples with HPV16 DNA should be visible on the gel 
because HPV16 primers are also present. However, for the HPV18 LAMP assay, 
there should be no products visualized because there are no HPV16 primers in 
the LAMP assay to amplify HPV16 DNA. There were very faint signals for the 
HPV18 LAMP products.  
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Figure 34: Agarose gel results for mLAMP and the FAM (HPV16) filter. 
  
Similarly, for HPV18 LAMP (Figure 35), the Texas Red filter was used to 
visualize HPV18 products. The bands should be present in mLAMP and HPV18 
LAMP, but not in HPV16 LAMP. These results are shown in the figure below, as 
the HPV16 LAMP gel was very faint whereas the bands in the other two assays 
were dark and distinct. From this experiment, the LLOD of each assay for each 




Figure 35: Agarose gel results for mLAMP and the Texas Red (HPV18) filter. 
 
Successful mLAMP tube assay 
A mLAMP assay was developed by combining the singleplex HPV16 and 
HPV18 assays into one 25 µl reaction. The HPV16 samples were labelled with 
FAM while the HPV18 samples were labelled with DIG, and a 2:1 ratio of HPV16: 
HPV18 LAMP primers was utilized (Figure 36). This was the first demonstration 
of 12 primers in a single reaction for HPV16 and HPV18 LAMP. The negative 
controls of the NTC and Jurkat cell DNA did not have amplification in tube or 
LFS, while the positive controls all had positive amplification in tube and LFS. 
The HPV16 sample generated a FAM line on the LFS, the HPV18 generated a 
DIG line on the LFS, and the combined HPV16+18 samples had FAM and DIG 
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lines on the LFS (Figure 36). This effectively proved the concept of the schematic 
(Figure 28) described at the start of this chapter. Having a multiplexed reaction 
allows the simultaneous detection of both targets in one reaction chamber, 
capturing 70% of the HPV’s that can cause cervical cancer. Note that these 
lateral flow strips did not contain a control line (as per the manufacturer), but 
proper flow was visually confirmed. 
 
Figure 36: Successful mLAMP in gel and LFS. 
 
The fluorescent workflow can determine which HPV genotypes are 
present (Figure 37). In order to achieve fluorescent imaging and LFS results, a 
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1:1 ratio of Texas Red: DIG was used with the HPV18 LF primer because DIG 
was not fluorescent. For the HPV16 LF primer, only FAM was used because this 
could be visualized with fluorescent imaging and LFS. The other reagents in the 
mastermix were obtained by adding half of the optimized recipes for each of the 
two HPV types. With the conventional ethidium bromide (EtBr)-stained agarose 
gel, the HPV16+18 DNA samples in the experiment would appear positive as 
HPV16 DNA and HPV18 DNA, but my method demonstrated that HPV16+18 
DNA sample #1 had HPV18 only DNA whereas HPV16+18 DNA sample #2 had 
HPV16 DNA only. This indicated that further mLAMP optimization was needed to 
ensure HPV16 DNA and HPV18 DNA both amplified in this combined sample. 
The insight provided by this method enabled LAMP troubleshooting and 
optimization without the need to perform downstream assays such as restriction 
enzyme digests or LFS. 
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Figure 37: Troubleshooting mLAMP with fluorescent imaging. 
 
Optimized singleplex and mLAMP with merged fluorescence images 
 
Control experiments of singleplex HPV16 and HPV18 LAMP were 
performed concurrently with the mLAMP to ensure the singleplex assays were 
amplifying as expected. After LAMP amplification for the HPV16 singleplex 
LAMP, HPV18 singleplex LAMP, and HPV16+HPV18 multiplexed LAMP assays, 
pvuII digests were performed for all samples overnight at 37°C. The samples 
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were then run on acrylamide gels and imaged using the FAM and Texas Red 
filters. The samples were also run on lateral flow strips. NTC and Jurkat cell DNA 
were used as negative controls for all assays. Different DNA concentrations were 
tested to determine the lower limit of detection of each lamp assay for the three 
different DNA types – HPV16, HPV18, and HPV16 + HPV18. 
First, the HPV16 singleplex LAMP was selective for HPV16 DNA. When 
HPV16 DNA was not present, there was no amplification. The negative controls 
of the no template control (NTC) and Jurkat DNA without HPV showed no 
amplification on the gel or strips. There was positive amplification when samples 
had the 96 bp FAM band (Figure 38). This was true for 105 and 103 copies of 
HPV16 DNA. HPV18 DNA samples did not have any FAM fluorescence or 96 bp 
bands, while the HPV16 +18 DNA samples had the fluorescent 96 bp FAM 
bands, as expected because there was HPV16 DNA in the sample. This was 
supported in the LFS results, which only had positive FAM test lines for the 
samples containing HPV16 DNA. In the SYBR-Green stained gel, the results of 
the unstained gel were reinforced, with positive amplification found only in the 
samples containing the 96 bp FAM band. The SYBR-Green gel confirmed that 
DNA was present. All three characterization schemes (unstained gel, stained gel, 
and LFS) matched the same results. 
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Figure 38: HPV16 LAMP LLOD with fluorescent imaging and LFS using FAM. 
 
Second, HPV18 singleplex LAMP was selective for HPV18 DNA down to 
105 copies. When HPV18 DNA was not present, there was no amplification. The 
negative controls of the no template control (NTC) and Jurkat DNA without HPV 
showed no amplification on the gel or strips. There was positive amplification 
when samples had the 127 bp Texas Red band (Figure 39)This was true for 105 
copies, but not for 103 copies of HPV18 DNA, which was below the LLOD. 
HPV16 DNA samples did not have any 127 bp bands, while the HPV16 +18 DNA 
samples had the fluorescent 127 bp Texas Red bands, as expected because 
there was HPV18 DNA in the sample. The fluorescent gel results were supported 
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in the LFS results, which only had positive DIG test lines for the samples 
containing HPV18 DNA down to 105 copies. In the SYBR-Green stained gel, the 
results of the unstained gel were reinforced, with positive amplification found only 
in the samples containing the 127 bp Texas Red band. The SYBR-Green gel 
confirmed there was DNA present. As was found with the HPV16 singleplex 
LAMP assay, all three characterization schemes (unstained gel, stained gel, and 
LFS) had the same results. 
 
Figure 39: HPV18 LAMP LLOD with fluorescent imaging and LFS using Texas Red and 
DIG, respectively. 
 
 Lastly, the mLAMP assay was selective for HPV16 DNA down to 104 
copies, for HPV18 DNA down to 103 copies, and for HPV16+HPV18 DNA down 
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to 104 copies of each (Figure 40). The negative controls of the no template 
control (NTC) and Jurkat DNA without HPV showed no amplification on the gel or 
strips. For the HPV16 DNA only samples, the 96 bp band was present at 105 
copies and 104 copies, but not for 103 copies, showing that the limit of detection 
for mLAMP and HPV16 DNA was 104 copies. For the HPV18 DNA only samples, 
the 127 bp band was present at 105, 104, and 103 copies, showing that the limit of 
detection for mLAMP and HPV18 DNA was 103 copies.  In the combined 
samples of HPV16 + 18 DNA, the characteristic fluorescent bands of each DNA 
type – 96 bp for HPV16 and 127 bp for HPV18 – were both present at 104 
copies. They were absent at 103 copies, showing that the LLOD for mLAMP with 
HPV16 + 18 DNA was 104 copies.  
Similar to before, the LFS results supported the amplification results of the 
fluorescent gel. There were faint FAM lines for the negative controls of NTC and 
Jurkat, even though these samples did not have the 96 bp band. I hypothesized 
this faint background signal to be a consequence of multiplexing LAMP with 12 
primers and examined this result further in Aim 3. In the SYBR-Green stained 
gel, the same results as the unstained gel were obtained and positive 
amplification corresponded to the samples containing the characteristic 
fluorescent bands. The SYBR-Green gel confirmed there was DNA present. As 
was found with the HPV16 singleplex LAMP assay and HPV18 singleplex LAMP 
assay, all three characterization schemes (unstained gel, stained gel, and LFS) 
had the same results. 
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Figure 40: Optimized mLAMP with 2:1 ratio of HPV16:18 primers 
 
Final mLAMP conditions and summary 
The in-tube reaction for mLAMP was carried out in a final volume of 25 µl 
with 1 µl of the DNA sample, 10x Isothermal Amplification Buffer (New England 
Biolabs), 8 U Bst 2.0 DNA polymerase, 0.9 mM dNTPs, 0.65 M betaine, 3.35 
pmol each of HPV16 forward and reverse primers (F3 and B3), 26.67 pmol each 
of HPV16 forward and reverse inner primers (FIP and BIP), 13.33 pmol each of 
HPV16 forward and reverse loop primers (LF and LB), 1.67 pmol each of HPV18 
forward and reverse primers (F3 and B3), 13.33 pmol each of HPV18 forward 
and reverse inner primers (FIP and BIP), and 6.67 pmol each of HPV18 forward 
and reverse loop primers (LF and LB). 
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A 2:1 ratio for HPV16:HPV18 LAMP primers was found to be optimal by 
enabling similar amplification times for the same concentrations of HPV16 and 
HPV18 DNA, as determined by the real-time instrument data. More HPV16 
primers were needed for amplification and this discrepancy with HPV18 primers 
was hypothesized to be due to resource competition among the two HPV primer 
sets. Amplification for an input of 105 cp was achieved in 30 minutes, so the 
reaction time was chosen to be 45 minutes to ensure complete amplification. 
After thorough assay optimization, HPV16 and HPV18 LAMP were multiplexed 
without cross-reactivity and retained the same LLOD as the singleplex LLODs. 
The mLAMP tube assay had a LLOD of 104 copies for HPV16 DNA, 103 
copies for HPV18 DNA, and 104 copies for HPV16+18 DNA. These are all 
clinically relevant concentrations for HPV16 DNA and HPV18 DNA. To test the 
likelihood of nonspecific primer interactions, a NTC only LAMP reaction was 
conducted for 45 minutes at 63°C. 0/21 samples were positive from PCR (data 
not shown), showing that there was very low likelihood for nonspecific primer 
interactions using these primer sets.  
 
3.4 Conclusions 
In this Aim, a multiplexed LAMP assay was achieved for HPV16 and 
HPV18 LAMP simultaneously that amplified at 63°C for 45 minutes. To confirm 
reaction specificity, the digest products of both singleplex LAMP reactions were 
sequenced. Sequencing is rarely attempted for LAMP products because of the 
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daunting number of amplicons, but a restriction enzyme digest after LAMP 
collapsed the number of amplicons into a manageable few that can be 
sequenced. I extracted these digested products and sequenced them via cloning 
into a pGEM vector for HPV16 product and a pET vector for HPV18 product. No 
modifications to the standard LAMP protocol (i.e. changing the LAMP primers to 
include sequence tags80) were needed to obtain products suitable for 
sequencing. The sequencing results revealed digested segments of LAMP 
amplicons that matched the target DNA sequence (Figure 31, Figure 33), 
providing direct proof that the amplicons were from specific target DNA rather 
than from non-specific primer interactions.  
The mLAMP tube assay was further characterized with the fluorescent 
workflow. mLAMP was performed in tube with fluorescent probes to differentiate 
HPV16 or HPV18 LAMP products. HPV16 LAMP amplicons were tagged with 
FAM, while HPV18 LAMP amplicons were tagged with a 1:1 mixture of Texas 
Red for fluorescent imaging and DIG for lateral flow strip detection. Using the 
fluorescent assay, the gel provided fluorescent information about what type of 
HPV was present after amplification. HPV16 products appeared only under the 
FAM filter, while HPV18 products appeared only under the Texas Red filter. The 
merged image was constructed with ImageJ and provided color indication for 
each HPV type. The clinically relevant LLODs of each singleplex assay were 
retained in the mLAMP assay, with 104 copies for HPV16 and 103 copies for 
HPV18. In Aim 3, this multiplexed tube assay was translated to a chip format. 
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Chapter 4: Chip Design and Development 
This chapter focuses on Aim 3 and the chip development to determine the 
optimal paperfluidic platform chip for LAMP and clinical samples (Figure 42). 
 
Figure 41: Adapting mLAMP to a paper platform for clinical samples schematic. 
 
Two chip options with different chip housing were investigated – the 
Fellowes adhesive chip and the cyclic olefin polymer (COP) chip. The mLAMP 
assay optimized in tube in Aim 2 was tested on both chips to assess the optimal 
chip performance. The Fellowes chip and COP chip were developed for the 
isothermal amplification assays of LAMP and helicase-dependent amplification 
(HDA), respectively. There were advantages and challenges for using both chips, 
but ultimately, the Fellowes chip was selected as the alpha prototype chip for 
LAMP testing.   
 96 
4.1 Significance 
The Fellowes chip was developed for LAMP previously in our lab 69. There 
were several advantages to using the Fellowes chip – it was easy to assemble 
(average time was 4 minutes) and consisted of adhesive sheets and paper 
materials that did not require additional heating to seal. However, it could be 
troublesome to operate, as it lacked a reaction chamber to hold the liquid 
volume, requiring many user pipetting steps. In addition, the tab removal after the 
LAMP reaction was often difficult because it required peeling apart the bond 
between two pieces of Fellowes adhesive.  
Therefore, a second chip – the COP chip – was designed to be more 
operationally robust than the Fellowes chip. The chip housing was changed from 
Fellowes adhesive to COP, a more rigid material. Layers of COP were stacked to 
create a reaction chamber to accommodate more volume and require fewer 
pipetting steps for the user. In addition, the problem with the tab removal after the 
LAMP reaction in the Fellowes chip was alleviated because the bond was now 
between a non-adhesive COP and adhesive Fellowes sheet. However, there 
were also challenges with using the COP chip. It was designed to work with 
HDA, not LAMP, and required the addition of mineral oil to the bottom of the chip 
to prevent condensation in the reaction chamber during heating. The HDA 
reactions had mineral oil in the mastermix reaction and were thus compatible 
with this additional mineral oil while LAMP did not perform well with the additional 
mineral oil. It was also more time-consuming and difficult to manufacture the 
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COP chips, as a Carver hot press was needed to bond the COP materials 
together, a process that took approximately an hour for 9 chips. 
 
4.2 Materials and Methods 
Fellowes chip fabrication and operation 
 
Figure 42: Foldable, modular operation of the Fellowes chip. 
 
A Fellowes adhesive diagnostic chip was designed by our lab and tested with 
HPV16 LAMP and clinical samples. 69 The modularity and ease of fabrication 
made it possible to adapt this platform for a mLAMP application. The chip 
operation is shown in Figure 42. The chip was made out of 3 mm thick self-
adhesive sheets (Fellowes, Itasca, IL) and consisted of a 0.22 μm pore size	
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polyether sulfone (PES) membrane (Catalog #GPWP04700, EMD Millipore, 
Billerica, MA) reaction chamber, Whatman #3 paper (Sigma Aldrich, St Louis, 
MO) waste pad, and a commercial LFS with fluorescein (FAM), digoxigenin 
(DIG), and streptavidin detection lines (#D005–05, UStar Biotechnologies, 
Hangzhou China).		A lysed patient sample was applied to the PES reaction 
chamber that efficiently captured DNA. 51 After DNA extraction, the absorbent 
pad was ripped off and disposed as biohazard waste. LAMP amplification 
mastermix was added to the purified DNA and covered with a tab, preventing 
evaporation. The chip was applied on an Isotemp digital heat block (Fisher 
Scientific, Waltham, MA), reaction chamber side down, at 63°C for 30 min for 
amplification. After amplification, the tab was lifted up and peeled under the 
reaction chamber to expose the bottom of the PES to the LFS. 60 µl of water was 
added to the top of the PES reaction chamber and the amplicons wicked 
vertically down onto the LFS (termed the gravity method, which will be explored 
later) to obtain a visible readout of the products.  
 
COP chip operation 
A cyclic olefin polymer (COP) diagnostic chip was designed in our lab and 
tested with Neisseria gonorrhoeae (NG) HDA and clinical samples. 50 HDA is 
another isothermal amplification technique that utilizes helicase and DNA 
polymerase to unwind and amplify the DNA, respectively (Figure 43). The 
improved chip operation when compared to the Fellowes adhesive chip made it 
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worthwhile to investigate its compatibility with LAMP. Figure 44 shows the chip 
operation for HDA. 
 
Figure 43: Schematic of Helicase Dependent Amplification (NEB website). 
 
The same steps were conducted when performing LAMP on the chip, except the 
HDA mastermix was replaced with LAMP mastermix.  
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Figure 44: COP chip operation with HDA. 
 
The chip was made out of 188 μm thick cyclic olefin polymer sheets (Zeon 
Chemicals, L.P., Louisville KY), Whatman # paper waste pad, and Fellowes 
adhesive sheets. The main functional components are the PES reaction 
chamber, absorbent waste pad, and LFS. 15 µl of mineral oil was placed on the 
bottom of the PES reaction chamber to eliminate the air bubble that would 
condensate during heating. An HPV DNA sample was applied to the PES 
reaction chamber. After DNA extraction, the absorbent pad was ripped off and 
disposed. LAMP amplification mastermix was added to the purified DNA and 
covered with an adhesive tab, preventing evaporation. The chip was applied, 
reaction side down, to a heat block at 63°C for 30 minutes for amplification. After 
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amplification, the adhesive tab was peeled from the COP to expose the PES 
chamber. 60 µl of water was added to the PES and a LFS was dipped into the 
PES to obtain a visible readout of the products. 
 
COP chip fabrication – washing and heat press conditions 
COP chips were washed with 80 µl of acetone and allowed to dry before 
being heat pressed at 258°F. There were two Carver heat press steps to ensure 
even bonding of the COP. The original COP chip fabrication protocol had the first 
press for 10 minutes at 3 metric tons and the second press for 7 minutes at 3 
metric tons. Both steps were experimented with for the new Kapton film 
modification. In the optimized COP chip conditions, the first press was 15 
minutes at 3 metric tons and the second press was 25 minutes at 1.5 metric tons.  
 
Stable heat source for amplification 
The previous hot plate used in the lab had analog temperature knobs and 
was not able to adequately maintain a consistent temperature. Significant efforts 
were required from the user to monitor the temperature during chip runs and to 
cool or heat the plate in real time. This was problematic and not sustainable, so a 
new digital Isotemp hot plate (Fisher Scientific, Waltham, MA) was used (Figure 
45). With this heater, temperature could be set digitally and the hot plate ramped 
up to the set temperature within 15 minutes. In addition, to maintain a steady 
temperature over the 30-60 minutes needed for amplification, a Styrofoam lid 
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with a metal weight was used to insulate the chips from temperature fluctuations. 
All experiments utilized the Isotemp hot plate set at 63°C. Thermocouple leads 
were connected to the hot plate surface to measure and monitor chip 
temperature during amplification.  
 
Figure 45: Digital hot plate set up for sustained heating of chips. 
 
Translating the mLAMP assay to the Fellowes chip  
The reaction conditions used for the mLAMP tube assay were translated 
directly onto the Fellowes chip. Reagents were mixed and pipetted onto the PES 
reaction chamber. The chip was heated face down on an Isotemp digital hot plate 
(Fisher Scientific) for 45 minutes at 63°C. After heating, the LAMP amplicons 
were eluted onto a lateral flow strip by lifting the reaction tab up and under to 
expose the bottom of the PES to the top of the LFS. 60 µl of water was applied to 
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the PES to elute the LAMP amplicons onto the LFS. The strips were imaged with 
the Nikon microscope after 5 minutes. 
 
Translating the singleplex HPV16 and HPV18 assays to Fellowes chip with 
LAMP and LFS steps using DNA standards 
 In this series of experiments, the DNA extraction step was excluded from 
the chip operation and performed at the bench. To simulate the precipitated DNA 
that would exist on the PES after DNA extraction, cloned DNA or water was 
added to the PES first. Then, LAMP mastermix was added to the PES. The chips 
were sealed tightly to prevent evaporation of the mastermix and put reaction side 
down on the hot plate set at 63°C. The temperature of the chip facing the hot 
plate was monitored using a thermocouple and was between 61-64°C the entire 
duration of the LAMP reaction, typically 45 minutes. After amplification, the chips 
were removed from the hot plate and the seal was removed to expose the bottom 
of the PES to the LFS. 60 µl of water was added to elute the amplified products 
onto the LFS, and results were visible within 5 minutes, at which they were read. 
The strips were then removed from the chip for imaging.  
 
Time-point experiments with singleplex LAMP and Fellowes chip 
 After initial tests showed amplification was positive without nonspecific 
amplification, time-point experiments were done to determine how quickly a DNA 
concentration could be amplified. At each time point, 2 chips were removed – 
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one negative and one positive sample. The objective was to determine the latest 
time at which the negative sample did not amplify and the earliest time at which 
the positive sample amplified. The upper limit was 45 minutes and the lower limit 
was 10 minutes. The chips were stored at 4°C until all time points were 
completed. Then, the chips were eluted onto LFS for readout determination and 
imaging. 
 
Two options for LFS loading – sample pad vs. conjugate pad 
Two options were tested to load the DNA sample onto the LFS. The LFS 
consists of a sample pad, conjugate pad, and waste pad. The DNA sample was 
conventionally loaded on the sample pad, but because there was such low 
volume in the COP chip after LAMP (likely due to the condensation from the lack 
of mineral oil), the sample pad was removed to allow direct access to the 
conjugate pad that contained gold nanoparticles for visible detection. Thus, the 
sample pad was removed to dip LAMP samples directly on the conjugate pad, 
minimizing sample loss in the sample pad. Loading on the conjugate pad for the 
DIP method generated stronger test lines than the DIP method with an intact 
sample pad. This modification was used in the following experiments as the DIP 
method. 
For these reactions, amplicons were loaded on the conjugate pad 
containing streptavidin-coated gold nanoparticles (NPs) directly (Figure 46). The 
conjugate pad was comprised of nitrocellulose and gold NPs. The control 
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reactions were loading the amplicons on the sample pad that preceded the 
conjugate pad. After loading the amplicons, 30 µl or 60 µl of water was applied 
as running buffer for the reactions starting on the conjugate pad and sample pad, 
respectively. Results were available in 5 minutes and imaged with the Nikon 
microscope.  
 
Figure 46: LFS loading with a conjugate pad (top) or sample pad (bottom). 
 
Two methods for LFS elution – gravity vs. dip 
For LFS elution, the “Gravity” and “Dip” methods were tested. The gravity 
method was based on the original Fellowes chip configuration, where the LFS 
was underneath the PES and amplicons flowed vertically down into the LFS. The 
dip method was based on the COP chip configuration, where the LFS was 
dipped into the PES from above, generating flow upward instead of downward. 
The gravity method was paired with the sample pad loading, while the dip 
method was paired with the conjugate pad loading, as described in the previous 
section. 
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For each chip, the reaction was first eluted using the dip method and then 
with the gravity method. Because high concentrations (106 copies) of DNA were 
amplified, there were more than enough amplicons to run two (and likely more) 
strips. Amplification was saturated to ensure amplicons were present to test the 
two methods. After elution, the strips were removed from the chip and imaged. 
 
4.3 Results and Discussion 
Testing the COP chip with HPV18 LAMP 
There were several advantages to the COP chip which made it an 
attractive option to explore for LAMP. First, there was no adhesive-adhesive 
contact, easier chip operation, and less risk of contamination because it was 
easier to open and remove the tab after amplification. HPV18 LAMP with FAM-
tagged primers and HPV18 DNA was performed in the original configuration of 
the COP chip for 45 minutes at 63°C (Figure 47). After 45 minutes, the negative 
samples did not amplify while the positive samples of HPV18, 105 copies of DNA 
amplified, as indicated by the presence of the FAM line on the LFS. The positive 
control of the NG HDA assay also had a positive FAM line, ensuring the 




Figure 47: Preliminary HPV LAMP test with COP chip. 
 
Adapting the COP chip for LAMP 
After the preliminary HPV18 LAMP experiments in the COP chip, several 
differences between the HDA and LAMP operations were observed. The biggest 
difference was the interaction of the amplification mixture with the mineral oil on 
the bottom side of the reaction chamber. The mineral oil was used to prevent 
condensation that occurred when the air bubble on the bottom side of the 
reaction chamber was heated. The mineral oil was compatible with the HDA 
reaction mastermix, which also contained mineral oil. However, the mineral oil 
was not compatible with the LAMP reaction mastermix, which did not contain 
mineral oil. After heating and tab removal, the LAMP reaction flowed from the top 
of the PES to the bottom of the PES which contained mineral oil. This resulted in 
no liquid containing amplicons for the LFS to dip into and elute from on the top 
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side of the PES. 60 µl of water was placed in the reaction chamber and the LFS 
was dipped in, but the results were not ideal because the amplicons had flowed 
to the other side of the reaction chamber and were inaccessible. Therefore, 
mineral oil was not used for LAMP reactions with the COP chip.  
 
Optimization of COP Chip Fabrication  
Many strategies were explored to simplify and optimize the COP chip 
fabrication method, which required significant dexterity, finesse, and time 
(approximately 1 hour to make 9 chips). First, Kapton tape was used to hold the 
folded COP and PES during the heat press as opposed to the previous method 
of applying constant pressure with the steel platens (Figure 48). This was easier 
to maneuver because the chips were able to sit by themselves flat after the PES 
was placed. Now, more than 9 chips could be fabricated at once because the 
process was not limited by the space on the platen. There was also a decreased 
risk of the PES moving to an undesired location beyond the sample port. Another 
modification to the fabrication was to remove the kapton film before the second 
press of 10 minutes, which generated flatter and more bonded chips. 
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Figure 48: COP chip fabrication optimization with kapton tape. 
 
PES bowing or curving was observed after the second heat press, as 
shown in the right most image of Figure 48. Both heat press steps were at 258°F. 
After the first heat press, there was no PES bowing, but the COP was not fully 
bonded. Prevention of PES bowing needed to be balanced with sufficient COP 
bonding. Therefore, the pressure was decreased from 3 metric tons to 1.5 metric 
tons for the second press. The resulting chips had less PES bowing but less 
bonded COP, as can be seen by the COP material not being clear. Next, the time 
was increased from 10 to 25 minutes for the second press at 1.5 metric tons. In 
these chips, there was also less PES bowing. The COP was more bonded near 
the sample port but had unbonded pockets away from the sample port. This 
could be due to uneven pressure applied to the chip from the heat press. In all 
cases, the PES bowing was on the shiny side of the PES which did not come into 
direct contact with the master mix, so the bowing may not have affected 
amplification. The priority was to obtain even COP bonding to mitigate the risks 
of COP delamination and loss of the chip’s structural integrity. 
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mLAMP in COP chip 
mLAMP, as well as singleplex HPV16 and HPV18 LAMP assays as 
controls, were performed with the COP chip at 65°C for 45 minutes (Figure 49). 
The asterisks (*) indicated desired results. All of the tube controls amplified as 
expected, but only 3 out of 9 chips amplified. 
 
Figure 49: mLAMP in COP Chip Experiment 1. 
 
In the next experiment, the temperature was decreased to 63°C. The chip 
results improved and 6 out of 9 chips amplified (Figure 50). All of the tube 
controls performed as expected except for HPV16 DNA in the HPV18 singleplex 
LAMP assay. The use of DNA Away for cleaning was also increased during all 
steps (fabrication, loading mastermix, detection) to minimize the chance of 
nonspecific amplification. However, there may have been HPV16 contamination 




Figure 50: mLAMP in COP Chip Experiment 2. 
 
Contamination with FAM-tagged HPV16 amplicons or DIG-tagged HPV18 
amplicons was hypothesized to be the cause of the false positive FAM and DIG 
results on the LFS. Therefore, the experiment was repeated with more stringent 
cleaning measures during all steps of chip fabrication and chip operation moving 
forward. Single-use reagent aliquots were also implemented. The bio safety hood 
designated for chip fabrication was extensively cleaned and all paper materials 
(Fellowes adhesive, PES, waste pad, lateral flow strips) were moved and stored 
in a separate room. One piece of Kapton film was used to create an envelope 
that the chips were placed in before they were put in the hot press, and new 
envelopes were made each time chips were fabricated. Previously, two pieces of 
Kapton film (one for the top, one for the bottom platen) were re-used for each 
fabrication. The hot press was cleaned with DNA Away before and after each 
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use. During chip operation, the Isotemp hot plate was cleaned with DNA Away 
before and after each use. In these results, only 4/9 chips amplified as expected, 
and there was unwanted FAM and DIG amplification (Figure 51).  
 
Figure 51: mLAMP in COP Chip Experiment 3 – chip samples. 
 
When the tube controls were run on strips in triplicate, the false positive 
amplification of the NTC samples was found to be attributed to the HPV18 LAMP 
assay, as all of the tube controls for HPV16 LAMP amplified as expected (Figure 




Figure 52: mLAMP in COP Chip Experiment 3 – tube controls. 
 
Using new HPV18 primers, mLAMP was performed in the COP chip again 
at 63°C for 45 minutes on the hot plate. The results showed significant FAM line 
contamination, despite the new HPV18 primers (Figure 53). Only 4/9 tube 
controls and 2/9 chips amplified as expected. Despite the increased cleaning 
measures and single-use aliquots, the unwanted FAM (and to a lesser degree, 
DIG) lines were still positive for almost all samples run with the COP chip. 




Figure 53: mLAMP in COP Chip Experiment 4. 
 
Translating mLAMP to Fellowes chip – initial tests 
mLAMP was performed in the Fellowes chip for 45 minutes at 63°C on the 
hot plate. There were three replicates per DNA sample, and of these replicates, 1 
or 2 utilized the Dip method for elution onto the LFS. The other replicates were 
eluted using the conventional Gravity method where the amplicons flowed onto 
the LFS underneath.  
For the NTC samples, the dip samples generated expected negative 
results where only the biotin control line appeared (Figure 54). However, the 
gravity samples generated a FAM test line in addition to the biotin control line. 
Because of this, the dip method was hypothesized to adsorb less DNA for elution 
than the gravity method. For the HPV16 DNA samples, the LFS results were as 
expected, with the presence of a FAM line and control line (Figure 54). Again, the 
hypothesis that the dip method adsorbed less DNA for elution was supported 
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because a control line appeared for replicate 3, the dip sample, suggesting there 
were excess streptavidin beads to bind the control line.  
 
Figure 54: mLAMP in Fellowes chip. Negative controls and HPV16 samples. 
 
For the HPV18 DNA samples, there was a DIG line for only 1 replicate 
(Figure 55). The other two replicates had positive FAM lines, which was not ideal. 
Similarly, the dipped sample, replicate 3, had the faintest test line, suggesting the 
dip method was not as effective at capturing amplicons for LFS than the gravity 
method. Lastly, for the combined HPV16+18 DNA samples, all 3 replicates 
showed only FAM lines (Figure 55). There were no DIG lines. Overall, this 




Figure 55: mLAMP in Fellowes chip. HPV18 and HPV16+18 samples. 
 
Translating mLAMP to Fellowes chip – one reaction vs. two reactions 
HPV16+18 mLAMP was performed as one multiplexed reaction of 
HPV16+18 LAMP and as two singleplex reactions of HPV16 LAMP and HPV18 
LAMP to see if the combination of the reactions was the cause of the NTC 
amplification. I hypothesized that the singleplex reactions would lead to 
background reduction in the LFS. 
For the mLAMP as one reaction, the HPV16+18 DNA at 106 cp sample 
amplified in 25 minutes. However, the NTC sample amplified in 10 minutes. In 
addition, there were false positive LFS results for the NTC samples of mLAMP 
(Figure 56).  
 117 
 
Figure 56: mLAMP as 1 reaction on Fellowes chip. 
 
Curiously, these false positive LFS results were not reciprocated in the 
gels and PCR curves, which showed no amplification. This high background 
problem did not occur with singleplex LAMP. The combinations of 12 primers and 
2 DNA types on the PES membrane likely caused significant nonspecific primer 
interactions. Because of these inconsistent results, I concluded that mLAMP 
should be performed in 2 reactions with 1 chip/LAMP assay in order to 
demonstrate reliable amplification in the Fellowes chip without high background 
signals on the LFS. 
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Figure 57: mLAMP as 2 singleplex reactions on Fellowes chip. 
 
Troubleshooting positive FAM test lines for mLAMP NTC samples 
The LFS results for the mLAMP reaction on chip showed a positive FAM 
test line for the no template control (NTC) samples (Figure 56). This was a 
confounding result, as the tube controls were not positive in other detection 
methods: the real-time results did not have amplification curves and the gels did 
not have positive amplification results. In addition, the NTCs for the singleplex 
assays did not show up on the LFS (Figure 57). This meant that the false positive 
FAM occurred specifically for the LFS and for mLAMP.  
The lack of a ladder-like smear on the gel suggested that the product 
binding to the FAM line was generated by primers interacting nonspecifically with 
each other. The product was not long enough to be amplified and visible in other 
methods. In addition, because it was mLAMP-specific, perhaps the interaction of 
 119 
the HPV16 and HPV18 primers together caused the problem. The hypothesized 
problem interaction was HPV16 LF-FAM with HPV18 LB-Biotin, since FAM and 
biotin were needed to bind the FAM line and generate a positive result. The 
interaction of HPV16 LF-FAM and HPV16 LB-Biotin was the other possible 
combination for a positive FAM line, but this was not observed from the 
singleplex HPV16 LAMP assay.  
Troubleshooting the positive FAM result for the NTC samples led to a 
series of experiments. First, the products were heated for two min at 95°C after 
LAMP to break up potential secondary structure. These products were then 
applied to the LFS. The FAM line still appeared, which meant this heating step 
was not enough to denature or the causative product could not be denatured 
(Figure 58). 
 
Figure 58: Experiment 1. mLAMP with post-LAMP heating. 
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 Then, I performed mLAMP without HPV16 LF-FAM and HPV18 LB-Biotin, the 
hypothesized problematic primers (Figure 59). HPV16 LF-FAM was hypothesized 
because the FAM tag enabled a FAM test line result while HPV18 LB-Biotin was 
hypothesized because the NTC result was mLAMP-specific and biotin was also needed. 
There was no FAM line in the singleplex HPV16 LAMP assay between HPv16 LF-FAM 
and HPV16 LB-Biotin. The results for this experiment were no FAM lines, which made 
sense as no FAM tags were available. FAM was needed in the primers for the FAM line 
to show up and the presence of the false positive FAM was not a random or nonspecific 
binding in the absence of FAM. 
 
Figure 59: Experiment 2. mLAMP with no HPV16 LF-FAM and HPV18 LB-Biotin. 
 
Next, I checked the sequence alignments of the HPV16 and HPV18 
primers. The IDT Oligoanalyzer and Fisher Multiple Primer Analyzer tools were 
used to determine the free energy of binding (DG’s) that corresponded to the 
stability of primer interactions. Self primers had a DG of -40 kcal/mol and this was 
the most stable interaction. Primer interactions between all 12 primers sets were 
in the range of -4 to -11 kcal/mol, which were not very significant. In addition, the 
ones with high DG’s did not have LF or LB. mLAMP with 12 primers was run as a 
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control experiment to confirm the NTC false positive FAM line was still an issue 
(Figure 60). The NTC samples had FAM lines while the positive samples had 
both FAM and DIG lines.  
 
Figure 60: Experiment 4. mLAMP with 12 primers as control experiment for NTC FAM 
result. 
 
Now that a primer interaction issue was suspected, DMSO was used to 
disrupt the primer interactions. DMSO is an organic solvent that breaks up primer 
interactions by disrupting hydrogen bonds. 2 µl of 99% DMSO was added to a 
12.5 µl mLAMP reaction. After amplification, the reaction mixture was applied to 
a LFS (Figure 61). The FAM lines still appeared for the NTC samples. Again, the 
real-time results and gel results were negative. Thus, the interactions between 




Figure 61: Experiment 5. mLAMP with DMSO. 
 
To flesh out the primer interaction issue, I tested LAMP with only the 
hypothesized problem primers of HPV16 LF-FAM and HPV18 LB-Biotin (Figure 
62). Water was substituted for the other 10 primers and the same LAMP 
conditions were run (63°C for 45 minutes). These amplicons produced positive 
FAM lines, which demonstrated that these two primers were sufficient to produce 
the problem and were likely the cause. 
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Figure 62: Experiment 6. LAMP with only HPV16 LF-FAM and HPV18 LB-Biotin. 
 
To determine if the FAM line was HPV16 or HPV18-specific, the FAM and 
DIG tags were switched so that HPV16 LF contained DIG and HPV18 LF 
contained FAM. HPV16 LB and HPV18 LB retained their biotin tags. In these 
amplicons, the NTC had DIG lines (2/3 samples), which suggested the product 


















Figure 63: Experiment 7. mLAMP with HPV16 LF-DIG and HPV18 LB-Biotin. 
 
The mastermix solutions before amplification of experiments 4-7 were 
tested on the LFS to serve as a no amplification control to assess if the FAM 
lines existed before amplification. Surprisingly, these mixtures all had positive 
FAM lines for the NTC (Figure 64). This strongly suggested that the primer 















Figure 64: Experiment 8. LFS of the mastermixes from Experiments 4-7. 
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The results from Experiments 1-8 corroborated the hypothesis that HPV16 
LF-FAM and HPV18 LB-Biotin were problematic primers and nonspecific primer 
interactions were underway that could be the source of the false FAM line. Thus, 
I focused on solving those 2 problems with Experiments 9 and 10, respectively. 
In Experiment 9, HPV16 LF-FAM concentrations were titrated to see if the 
NTC FAM line problem would decrease, since HPV16 LF-FAM was the source of 
FAM. LAMP can still amplify without loop primers and loop primers were added 
to include relevant tags on the amplicons for LFS binding. 20 µM was the 
standard concentration for HPV16 LF-FAM and the concentrations tested were 1, 




Figure 65: Experiment 9. mLAMP with HPV16 LF-FAM titrations. 
 
In Experiment 10, Jurkat DNA was added as carrier DNA to block 
nonspecific primer interactions. 1, 10, 100 ng of Jurkat DNA were tested (Figure 
66). The NTC amplicons of these samples still had lines so the carrier DNA was 
not enough to block the nonspecific primer interaction. 
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Figure 66: Experiment 10. mLAMP with 1, 10, 100 ng of Jurkat carrier DNA. 
 
In addition, the LFS was reversed to see if putting the biotin line first 
instead of the FAM line first would change the NTC FAM line from appearing 
(Figure 67). When this was done, the FAM lines did not appear for the NTC. This 
suggests that having biotin first instead of FAM could screen for true negatives 
and what was binding may simply have bound to whichever line was first.   
 
Figure 67: Experiment 11. Reversing the LFS for mLAMP Experiment 4. 
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Lastly, the tags in the HPV16 loop primers were switched to remove the 
hypothesized problematic interaction of HPV16 LF-FAM and HPV18 LB-Biotin. 
Therefore, HPV16 LF-Biotin and HPV16 LB-FAM were used with HPV18 LF-DIG 
and HPV18 LB-Biotin (Figure 68). The sequence-specific interaction between 
HPV16 LF and HPV18 LB could still occur, but now it would be tagged with biotin 
only, which would not be able to bind to the FAM line. A potential pitfall with this 
strategy is if there was also an interaction between HPV16 LB and HPV18 LB. 
Before, this was a biotin only interaction but with the tags switched, this could 
lead to a FAM-biotin product that could bind to the FAM line. The results showed 
that there were no FAM lines when the tags were switched. This tag switch 
effectively solved the problem of the NTC FAM line appearing by masking the 
hypothesized problematic primer interaction between HPV16 LF-FAM and 
HPV18 LB-Biotin. However, further testing with this newly tagged primer set 
generated nonspecific positive FAM lines for NTC and HPV18 samples, both of 
which should not have contained FAM. Therefore, this suggests there are other 
problematic primer interactions at play to investigate in the future. 
 
Figure 68: Experiment 12. mLAMP with HPV16 LF-Biotin and HPV16 LB-FAM. 
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 Given all of these troubleshooting efforts, the conclusion was the HPV16 LF and 
HPV18 LB sequences were likely causing a primer interaction in the mLAMP 
assay that generated a false positive FAM line for the NTC samples. This false 
FAM line occurred without heat and was problematic for a mLAMP assay with a 
LFS readout. Nonspecific primer interactions were tested with these methods: 
1. Disrupted interactions via heat, DMSO, and primer changes (Experiments 
1, 4-6)  
2. Checked sequence alignment (Experiment3) 
3. Identified 16 LF-FAM and 18 LB-Biotin as the primers involved 
(Experiments 2, 6, 8) 
4. Determined this interaction to be HPV16-specific (Experiment 7) 
Therefore, moving forward with translation to the Fellowes chip, the mLAMP 
assay was separated into two singleplex assays and two chips to avoid the 
primer interaction issue between the two HPV LAMP assays. This series of 
experiments to investigate the NTC FAM result of mLAMP on LFS opened many 
lines of inquiry and strategies to consider for future multiplexing efforts. The 
troubleshooting experiments are summarized below (Table 5). 
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Dip vs. gravity methods for LFS elution 
With the dip method, an issue of background signal for positive LAMP 
samples with an intact sample pad was observed (Figure 69). In addition to the 
test line, control lines also appeared for the positive samples where control lines 
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did not appear for the gravity positive samples. This result suggested that there 
was more DNA that bound to the NPs in the gravity samples, leaving less 
available for the control line. This result was observed in the NTC that amplified. 
There was a control line for the dip sample while there was no control line for the 
gravity sample.  
 
Figure 69: HPV18 LAMP in Fellowes chip – NTC and HPV16 samples. 
 
For the dip method, Replicates 2 and 3 of HPV16+18, 107 cp did not have 
a positive DIG line (Figure 70). Conversely, for the gravity method, all samples 
had positive DIG lines. It is highly unlikely that there was no amplification for DNA 
of this high copy number. Again, it was likely the dip method did not pick up as 
many DNA amplicons as the gravity method.  
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Figure 70: HPV18 LAMP in Fellowes chip – HPV18 and HPV16+18 samples. 
 
Overall, the results of the dip elution method were the same as those of 
the gravity elution method. However, there were higher intensity lines with the 
gravity method. More DNA was hypothesized to be eluted with the gravity 
method over time as opposed to the dip method which could only capture DNA 
upon first contact. The gravity method involved a steady flow rate through the 
PES to the LFS as opposed to the contact-based flow of the dip method.    
 
Loading samples on LFS via sample pad or conjugate pad 
To eliminate the possibility of DNA getting stuck in the sample pad and not 
flowing to the conjugate pad, the sample pad was removed and the sample was 
added directly to the conjugate pad. Replicates 1 and 2 of the dip method had 
conjugate pad loading, while Replicate 3 had sample pad loading. Replicates 1-3 
of the gravity method had sample pad loading. For the NTC samples, replicates 
2-3 were negative as expected, but Replicate 1 was positive for FAM in both the 
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dip and gravity methods (Figure 71). For the HPV16 samples, all replicates were 
positive for FAM in both methods. 
 
Figure 71: HPV16 LAMP with conjugate pad and sample pad loading – NTC and HPV16 
samples. 
 
For the HPV18 samples, all replicates were negative for FAM in both 
methods (Figure 72). For the HPV16+18 samples, Rep 3 for HPV16+18 in the 
dip method had a faint FAM line while it had a strong FAM line in the gravity 
method. Again, this supports the hypothesis that the sample pad could be 
retaining sample from the conjugate pad because Rep 3 was sample pad 
loading. For the HPV16+18 samples in the gravity methods, there were no 




Figure 72: HPV16 LAMP with conjugate pad and sample pad loading – HPV18 and 
HPV16+18 samples 
 
Overall, the results from the conjugate pad and sample pad loading were 
similar. Sample pad loading was chosen as the option moving forward to avoid 
unneeded dismemberment and handling of the LFS.  
 
Amplification efficiency in Fellowes chip 
Singleplex HPV16 and HPV18 LAMP assays amplified DNA standards in 
chip with approximately the same efficiencies as the real-time instrument. This 
was determined by comparing the amplification times on chip as determined by 
time-point experiments with the Ct values as calculated by the real-time 
instrument. 
For HPV16 LAMP, 10-20 minutes were tested, with chips taken out every 
2 minutes (Figure 73). There was no nonspecific amplification in 10-20 minutes. 
The dip NTC samples did not have the faint FAM lines as seen in the dip NTC 
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samples of HPV18 LAMP (see next section), even though HPV16 LAMP 
contained FAM reagents.  
 
Figure 73: HPV16 LAMP time point experiments in Fellowes chip with NTC samples.  
 
HPV16, 106 cp amplified in 12 minutes, which matched the real-time 
instrument's Ct (14-16 minutes) (Figure 74). However, the FAM test line was faint 
at 12 minutes, so 16 minutes was preferred. The assay time was chosen to be 30 
minutes to ensure HPV16, 105 cp amplification (which had a Ct of 18 minutes). 
Overall, the dip results matched the gravity results, but the gravity results had 
darker FAM lines. 
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Figure 74: HPV16 LAMP time point experiments in Fellowes chip with HPV16, 106 cp 
DNA samples.  
 
For HPV18 LAMP, 10-20 minutes were tested, with chips taken out every 
2 minutes (Figure 75). There was a curious result of faint FAM lines appearing for 
the NTC samples that were eluted with the dip method. This did not exist for the 
NTC samples that were eluted with the gravity method. The lines also did not 
appear in the positive DNA control samples eluted with dip or gravity methods. 
 
Figure 75: HPV18 LAMP time point experiments in Fellowes chip with NTC samples. 
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106 cp of HPV18 DNA amplified in 16 minutes, which matched the real-
time instrument's threshold time (16-18 min) (Figure 76). However, the DIG test 
line was faint, so 20 minutes was preferred. The assay time was chosen to be 30 
minutes to ensure HPV18, 105 cp amplification (which had a threshold time of 20 
minutes). 
 
Figure 76: HPV18 LAMP time point experiments in Fellowes chip with HPV18, 106 cp 
DNA samples. 
 
Gravity vs. Dip methods 
 A problem of faint FAM lines for HPV18 LAMP NTC samples eluted with 
the dip method was observed, even though there were no FAM-containing 
primers in the HPV18 mastermix. The FAM line was absent in the HPV16 LAMP 
dip samples, even though HPV16 LAMP had a FAM-containing primer. The 
appearance of the false FAM line could be due to a kinetic issue of flow that 
occurred too quickly which led to the gold nanoparticles drying on the line. 
Perhaps there was not enough liquid for the nanoparticles to flow to the control 
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line. However, it is curious that the FAM line was absent for HPV16 LAMP. 
Although the dip method would’ve been more convenient and less involved for 
the user, it generated false positive FAM lines and had lower test line intensities 
than those of the gravity method. Thus, moving forward, the more reliable gravity 
method was used for LFS elution.   
 
Comparing the COP chip vs. Fellowes chip – fabrication and operation 
There were several advantages and disadvantages to the fabrication and 
operation of the COP and Fellowes chip, respectively. For the COP chip, the 
disadvantages were difficulty with consistent manufacturing and PES bowing of 
various degrees, depending on the length and pressure of the heat press steps. 
Kapton film helped to achieve more uniform pressure of the heat press, but the 
chips still ‘sprung’ around after they had been taped down, causing the PES to 
shift from the center and be misplaced. For a set of 9 chips, the process 
comprised of 5 minutes of acetone washing and drying, 10 minutes of placement 
onto the platen sandwich, 40 minutes of heating, and 5 minutes of cooling. In 
total, it took approximately an hour to prepare 9 chips, of which generally 6/9 
were usable and had properly aligned PES that did not shift during fabrication 
and evenly bonded COP.  
Furthermore, the COP chip was developed and optimized for the NG HDA 
reaction, which contained mineral oil. The COP chip addressed the condensation 
that formed during heating by adding mineral oil to eliminate air. Mineral oil was 
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compatible with HDA, but not with LAMP, which does not have mineral oil in the 
mastermix and was not compatible with mineral oil in the chip. Mineral oil was 
removed for the LAMP reactions in the COP, which enabled condensation air 
bubble on the non-reaction side of the reaction chamber that may have changed 
the effective concentrations of each reagent and potentially caused differences in 
the amplification dynamics.  
The main advantage of the COP chip was easy operation because there 
was a reaction well to hold a larger volume than the Fellowes chip. Thus, there 
were fewer pipetting steps required of the user during the wash steps. In 
addition, the rigid housing eliminated adhesive-adhesive bonding, which made it 
easier to remove the tab after amplification. 
For the Fellowes chip, the disadvantages were difficult operation and 
several pipetting steps required because the reaction chamber was two-
dimensional and held 25 µl at most per addition. There was a tricky step after 
amplification that involved peeling the tab under to expose the PES to the LFS. It 
required the user to forcefully separate two pieces of adhesive and potentially 
touch the PES with amplicons, which led to a high risk of contamination and false 
positives. I tried to circumvent this by dipping the LFS into the PES, as is done 
for the COP chip, but this method generated false positive FAM lines for the 
negative samples. Instead, this problem was circumvented by making larger 
perforations around the tabs, which made it easier to peel away the adhesive-
adhesive bond without ripping or excessive handling of the chip (Figure 77). The 
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original perforations were 0.050 inches and the modified perforations were 0.150 
inches. 
 
Figure 77: Perforation change in Fellowes chip to improve operation. 
 
The advantages of the Fellowes chip were that it was developed for LAMP 
and was thus compatible with the LAMP reaction. It was also very easy to 
manufacture consistently, and took approximately 4 minutes to assemble each 
chip, a great advantage over the 1 hour it took to make 9 COP chips. 
With regard to heating, the heated Styrofoam lid was applied to insulate 
the chips and maintain a steady temperature below and above the chip in two 
directions. This worked well for the COP chip, but not for the Fellowes chips. 
Therefore, for subsequent Fellowes testing, the lid was removed, and the one-
directional heating improved amplification results.  
 
4.4 Conclusions  
After testing the Fellowes chip and COP chip for LAMP, the Fellowes chip 
was the optimal chip for LAMP and mLAMP. Significant efforts were made to 
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adapt the COP chip – originally designed for HDA assays – for LAMP, but results 
were unsuccessful as the LAMP results were inconsistent. However, the 
fabrication for the COP chip was improved with the addition of Kapton tape, and 
the balance between COP bonding and PES bowing was considered. 
Optimization of the Fellowes chip operation was also achieved. Namely, 
the challenge of the tab peeling after LAMP was removed by increasing the 
perforation distances, which prevented prematurely ripping of the tab. The overall 
hot plate setup was also improved by using a digital hot plate that could have a 
set temperature and ramp up to the set temperature in 15 minutes. 
Several chip modifications for the Fellowes chip were tested to improve 
function, such as 1) loading the DNA sample on the sample pad or conjugate pad 
and 2) eluting onto the LFS using a dip or gravity method. Sample pad loading 
and gravity elution were chosen to be optimal. Time optimization was achieved 
with time point experiments to determine the minimum time at which amplification 
of positive samples occurred without amplification of negative samples. For each 
singleplex assay, the reaction time was chosen to be 30 minutes. 
mLAMP as one reaction in the Fellowes chip led to false positive LFS 
results for the negative samples. Significant troubleshooting was performed to 
investigate the cause of the false positive LFS results, and the primer interaction 
between HPV16 LF and HPV18 LB was likely the issue. Therefore, the optimal 
chip configuration chosen for mLAMP was two singleplex chips, one for each 
assay of HPV16 LAMP and HPV18 LAMP.  
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Chapter 5: Clinical Samples Testing with Chip 
 
This chapter focuses on Aim 3 of my thesis work and utilizing the Fellowes 
chip as an alpha prototype chip with clinical samples. The goal of this work was 
to test the mLAMP reaction on the alpha prototype chip with clinical samples. It is 
rare that assay development completed for a benchtop process is directly 
translatable to a microfluidic chip platform. This work required extensive 
characterization to construct a well-defined library of clinical samples. The clinical 
samples were first characterized with PCR to determine the presence and 
amount of HPV16, HPV18, and RNAseP DNA in each sample. The results of any 
lab-based testing done on the samples prior to our lab receiving them was 
confirmed if possible. Some lab tests are able to detect more HPV strains than 
16 and 18 and will thus be negative in our test but positive in the lab-based test. 
These lab tests cannot tell which strain the samples are positive for, simply that 
one high-risk HPV strain is present.  
To characterize the samples, they were first extracted at the bench prior to 
PCR and quantification. For cell lysis and DNA extraction, an extraction protocol 
based on butanol precipitation was used and the extraction efficiency was 
compared to that of the gold standard QIAGEN DNA Easy Blood and Tissue kit. 
After an extraction method was chosen, the clinical samples were tested with 
mLAMP only (no sample preparation) in the alpha prototype chip, and results 
were compared to the PCR results. This small subset of clinical samples 
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demonstrated feasibility that mLAMP on the alpha prototype chip can be used in 




Importance of clinical samples as representative of field setting 
The final configuration of the chip is intended for use in low-resource 
settings (LRS) such as a remote medical clinic where cervical swab samples 
would be directly applied to the chip. It is important that the chip is designed to 
accommodate such samples in order to make an impact in the field and to be 
comparable to the existing LRS diagnostic options of the careHPV test (QIAGEN, 
Germantown, MD) and VIA testing. CareHPV uses a standard cervical swab 
while VIA requires no sample to be taken, as the test is performed and visualized 
directly on the patient’s cervix. To mimic this final sample type, the samples used 
with the alpha prototype chip were cervical swab samples. They were de-
identified and discarded samples that had undergone Cervista hr-HPV testing. 
These samples were kept as dry pellets after initial processing (see Materials 
and Methods), making them more comparable to the buffer-free swabs used in 
the field.  
 
Chip workflow and requirements 
 The chip design consisted of 3 modules – DNA extraction, amplification 
and detection. First, the cervical sample was collected, processed, and mixed 
with lysis buffer, which contained butanol, GuSCN, NaCl, and GlycoBlue 
Precipitant (ThermoFisher, Waltham, MA). The lysed sample was applied to the 
PES reaction chamber which captures DNA-glycogen precipitates, which are too 
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large to pass through the 0.22 µM pore size filter. The rest of the sample flowed 
through the PES and wicked onto the absorbent paper, which was subsequently 
removed and discarded as biohazard waste (theoretically, this waste should be 
sterile, since the sample has been exposed to alcohol and a chaotropic buffer). 
After DNA extraction, the DNA captured on the filter paper was amplified using 
LAMP and loop primers labeled with biotin, DIG, or FAM. After amplification, the 
amplicons flowed onto the lateral flow strip for detection. The final readout was a 
series of red lines whose positions indicated a negative or positive result for 
HPV16 DNA and HPV18 DNA. 
 
Lysis buffer components and requirements  
The lysis buffer consists of butanol, GlycoBlue Precipitant, NaCl, and 
GuSCN. Butanol’s low dielectric constant precipitates DNA out of solution by 
making the DNA less soluble. The low dielectric constant makes it easier for the 
Na+ from the NaCl to interact with the PO3- of the DNA backbone. This interaction 
leads to a less hydrophilic nucleic acid that can precipitate out of the solution. 
GlycoBlue Precipitant is a blue dye covalently linked to glycogen. Glycogen co-
precipitates with DNA to enhance the recovery of DNA, while the blue dye allows 
visual observation of the glycogen. Similar to the butanol, NaCl neutralizes the 
negative PO3- charges on the DNA backbone and makes the DNA less 
hydrophilic. GuSCN is a chaotrope which disrupts the hydrogen bonds between 
water molecules and helps to lyse cells for DNA extraction. It was added to 
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accommodate the clinical samples which contained cervical cells. 
 
5.2  Materials and Methods  
Clinical sample processing and DNA extraction 
Fresh patient cervical swab samples from liquid cytology were obtained 
from Dr. Rajan Dewar at Beth Israel Deaconess Medical Center (BIDMC). The 
samples were discarded samples under IRB exempt protocol #3231. The 
samples were de-identified liquid cytology patient samples from the high-risk (hr)-
HPV Cervista test. Cervical cells were collected with a brush and placed in a vial 
of 70% ethanol solution.  
After arrival at the Klapperich laboratory, the samples were centrifuged to 
pellet the cells. The supernatant was tested for cellular DNA using the QIAGEN 
Midi kit and there was negligible (<2 ng/µl) DNA present. In addition, because the 
samples were in 70% ethanol, any DNA would have precipitated out after 
centrifugation, resulting in a pellet. However, there was not a pellet after 
centrifugation (the first step of the Midi kit). For subsequent samples, the 
supernatant for subsequent samples was discarded. The pelleted cells were 
washed three times with 1x phosphate-buffer saline (PBS) and resuspended in 1-
5 mL of PBS, depending on the size of the pellet. 1 mL aliquots were made of the 
resuspended cell solution and centrifuged. The supernatant was removed, 
leaving a cell pellet for each aliquot that was then stored at -80°C.  
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DNA was extracted from the cell pellets using the QIAGEN DNeasy Blood 
and Tissue kit (QIAGEN) and the concentration of the purified DNA was 
determined by measuring the OD260 with the NanoDrop ND-2000c apparatus 
(Thermo Scientific, Waltham, MA). Samples with strong peaks at 260 nm were 
considered positive for DNA and deemed acceptable for further characterization 
by multiplexed PCR (mPCR). 
 
Clinical sample characterization with multiplexed PCR (mPCR) 
Because the patient samples were more complex and contained additional 
components than the cloned DNA standards in water that had been used as the 
samples to date, an internal control was needed to account for cellular DNA. 
RNAseP was used as a positive control for PCR to ensure there was cellular 
DNA and DNA extraction was successful. RNAseP is commonly used in the 
literature as a positive reference for human DNA. 
With the internal control identified, a multiplex PCR assay was developed 
to detect HPV16, HPV18, and RNAseP DNA concurrently. The primer sequences 
for this assay are listed in Table 6. The primers for HPV16 PCR were from 
Moberg et al. 81 
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Table 6: PCR primers for HPV16, HPV18, and RNAseP 
PCR PRIMER SEQUENCE 
HPV16_PCR_FWD AGC TCA GAG GAG GAG GAT GAA 
HPV16_PCR_REV GGT TAC AAT ATT GTA ATG GGC TC  
HPV16_PCR_PROBE /5CY5/CC AGC TGG ACA AGC AGA ACC GG/3IABKFQ/  
HPV18_PCR_FWD ATGTCACGAGCAATTAAGC 
HPV18_PCR_REV TTCTGGCTTCACACTTACAACA 
HPV18_PCR_PROBE  /56-FAM/CATCAACATTTACCAGCCCG/3BHQ_1/ 
RNASEP_PCR_FWD CATGAGGTTGGCCAGGCGCG 
RNASEP_PCR_REV GGGACTTCAGCATGGCGGTGT 
RNASEP_PCR_PROBE  /5HEX/TTCTGACCTGAAGGCTCTGCGCG/3BHQ_1/ 
 
 
The mPCR assay was tested with cloned DNA for HPV16, HPV18, and 
RNAseP. Reaction conditions (melting temperature, time) and reagent 
concentrations (MgCl2, primer sequences, primer concentrations) were optimized 
to enable robust amplification of all three targets in a similar time frame (2-3 
hours). After thorough optimization, the mPCR was used to characterize the 
clinical samples, which were run with a set of DNA standards from our cloned 
DNA stocks that had known concentrations of DNA.  
 
Testing extraction and amplification on chip with clinical samples 
In Chapter 4, I showed that DNA standards could be amplified on the 
alpha prototype chip. Here, the amplification of clinical samples was tested on 
the alpha prototype chip. DNA was extracted from clinical samples using the 
QIAGEN DNAeasy Tissue Kit or a butanol-based lysis buffer developed in our 
lab. After extraction on the chip, LAMP mastermix was applied and the chip was 
heated for 45 minutes at 63°C on a hot plate. After heating, the reaction was 
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eluted onto a LFS with 60 µl running buffer. Strips were allowed to dry and 
imaged using the Nikon scope.  
 
Lysis off chip and washing on chip 
In these experiments, lysis was performed off chip but washing remained 
on chip. The lysis reaction was mixed in a tube and centrifuged for 15 minutes at 
13000 rpm. The supernatant was removed and the blue glycogen DNA pellet 
was resuspended in 25 µl of water. The concentration of the resuspended DNA 
sample was measured with the Nanodrop apparatus to check for purity. The 
sample was applied directly to the PES chamber and washed with 70% and 
100% ethanol on the chip. The sample was dried for an excessive 2.5 hours to 
ensure ethanol was not in the PES to cause inhibition of LAMP. The long drying 
times were later shown to be unnecessary and were shortened to 15 minutes 
(data not shown). Afterwards, LAMP mastermix was added to the chip and the 
chips were heated on the hot plate for 45 minutes at 63°C. After amplification, 
LFS were run to determine which samples amplified. 
 
5.3  Results and Discussion 
mPCR optimized conditions 
The in-tube reaction for mPCR was carried out in a final volume of 25 µl 
with 5 µl of the DNA sample, 10x TaqMan Buffer (New England Biolabs), 0.5 U 
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Taq Polymerase, 3.6 mM MgCl2, 200 µM dNTPs, 1.25 pmol each of RNAseP 
forward primer, reverse primer, and probe, 1.25 pmol each of HPV16 forward 
primer, reverse primer, and probe, and 5 pmol each of HPV18 forward primer, 
reverse primer, and probe. The PCR reaction conditions were 10 minutes at 
95°C and 45 cycles of 95°C for 30 seconds, 55°C for 30 seconds, and 60°C for 
1.5 minutes. 
 
Characterization of patient samples 
mPCR was used to detect HPV16, HPV18, and RNAseP DNA 
simultaneously in QIAGEN-extracted clinical samples. DNA standards of known 
concentrations for each DNA type were also run on each plate to generate a 
standard curve from which to quantify the DNA concentrations in clinical 
samples. Figure 78 shows the real-time amplification data for RNAseP DNA 




Figure 78: Real-time mPCR data for RNAseP DNA standards. 
 
When the DNA standards are compared to the clinical samples, the copy 
numbers of the clinical samples can be calculated. A subset of samples was run 
with the mPCR assay (Figure 79). The copy numbers were calculated based on 
the standard curve of the DNA standards. The sample number is shown with the 
copy number, i.e. sample #104 had 1.4E4 copies of RNAseP DNA. RNAseP was 
used as a positive control for PCR to ensure there was cellular DNA and DNA 
extraction was successful. RNAseP is commonly used in the literature as a 
positive reference for human DNA. 
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Figure 79: Representative real-time mPCR data for RNAseP in clinical samples. 
 
Similar standards and calculations were performed for HPV16 (Figure 80, Figure 
81) and HPV18 (Figure 82, Figure 83) data.  
 
Figure 80: Real-time mPCR data for HPV16 DNA standards. 
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Figure 81: Representative real-time mPCR data for HPV16 DNA in clinical samples. 
 
Figure 82: Real-time mPCR data for HPV18 DNA standards. 
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Figure 83: Representative real-time mPCR data for HPV18 DNA in clinical samples. 
 
Currently, the inventory of samples that are above 104 cp (the LLOD of the 
mLAMP assay) are: 9 HPV16-/18-, 46 HPV16+, 5 HPV16+/18+, and 0 HPV18+.   
 
Alpha prototype chip with bench-extracted clinical samples  
The same clinical samples from the previous experiments were used in 
these experiments. However, instead of QIAGEN extraction, the butanol-based 
lysis buffer was used for extraction and is known as the “bench extraction” 
method. After bench extraction and two washes of 70% and 100% ethanol, the 
PES was allowed to thoroughly dry for 30 minutes before the LAMP mastermix 
was applied. After heating and elution of products onto the LFS, the results 
showed that HPV16 LAMP on the alpha prototype chip could not amplify or 
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detect bench-extracted clinical samples. Only 1 sample (Sample 90) had a faint 
FAM line on the LFS. While running the experiment, I observed leaking of the 
LAMP mastermix due to an uneven surface between the PES and tab after waste 
pad removal, which could be the reason for no amplification. Therefore, for the 
next experiments, I sought to test the effect of operational changes by increasing 
the sealing of the adhesive and washing of the PES. 
 
Figure 84: QIAGEN-extracted positive samples did not amplify on the alpha prototype 
(Fellowes) chip due to insufficient sealing. 
 
Increased sealing of the chip  
Efforts were taken to seal the chip thoroughly during chip fabrication and 
chip operation. Sealing during fabrication meant that the adhesive housing was 
pressed evenly after each addition of material, such as the PES and waste pad. 
During chip operation, the Fellowes adhesive was carefully smoothed out after 
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the waste pad was removed to ensure the reaction chamber was properly 
sealed. In these results, the tube controls amplified as expected, but none of the 
positive chip controls amplified (Figure 85). Similarly, none of the 3 clinical 
samples (Samples 63, 85, and 90) amplified. Therefore, increased sealing did 
not help the controls or clinical samples amplify in the chip. Thus, the next step 
was to examine potential inhibitors in the PES that were left over from the lysis 
buffer. This was achieved by increasing wash steps to remove the inhibitors.  
 I also tested cloned DNA samples that had been stored in PES for 5 days 
(Figure 85). These stored samples amplified, showing that purified DNA storage 
on the PES can amplify days later, which could be a useful route to pursue for 
long-term storage and application in field settings. DNA could be extracted and 
stored on the chip at room temperature before being brought to a more central or 
clean location to perform LAMP, which requires temperature-sensitive reagents.  
 
Figure 85: Increased sealing time and pressure for Fellowes chip did not improve 
results. 
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Increased washing on the chip  
To remove inhibitors from the PES after lysis on chip, increased washing 
was performed. Typically, the 2 wash steps are 200 µl of 70% ethanol and 100 µl 
of 100% ethanol. Doubling the 70% wash step to 400 µl did not help clinical 
samples or controls amplify (Figure 86). Therefore, the next experiment 
performed was a salt rescue experiment to test the hypothesis that there was 
residual salt in the PES after lysis that was possibly inhibiting the reaction. 
 
Figure 86: Increased washing of the alpha prototype chip did not improve amplification. 
 
Testing lysis/extraction buffer on chip 
After the extraction step, the PES was removed and centrifuged. The 
resulting recovered liquid was characterized using the Nanodrop apparatus. 
There was a high 240-250 nm peak in the Nanodrop reading that could 
correspond to the GuSCN or butanol in the lysis buffer. The peak was not 




Figure 87: Nanodrop readings before and after extraction for clinical sample #111. 
 
The following pictures show what the PES looked like after sample addition, after 
washing, and after PES removal for centrifugation and DNA recovery (Figure 88). 
 
Figure 88: PES reaction chamber post sample, wash, and removal, where the blue 
areas show the GlycoBlue-DNA precipitates. 
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Salt ‘rescue’ experiment 
After washing on chip, I hypothesized that salt (NaCl) was left behind from 
the lysis buffer (Table 7) on the PES and inhibited LAMP. The salt rescue 
experiment involved removing salt from the LAMP amplification buffer (NEB, 
Table 8) and determining if this reduced-salt mastermix would amplify on the 
chip. If there was sufficient salt on the PES, then amplification could occur. If 
there was not sufficient salt on the PES, then no amplification could occur. 
Table 7: Bench extraction lysis buffer components. 
 
Table 8: NEB isothermal amplification buffer components. 
 
The different buffers tested are listed in Table 9. To complicate matters, there 
were multiple salts in the LAMP amplification buffer (Buffer 1). They were 
ammonium sulfate, KCl, and MgSO4. MgSO4 could not be removed because 
magnesium was a co-factor for Bst. Therefore, the first 2 were removed one at a 
time and then both at once (Buffers 3-5). In addition, a control (Buffer 2) of all 
Lysis Buffer Components 
3M GuSCN 
35% Butanol 
300 mastermix NaCl 
Glycoblue 
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components of the LAMP amplification buffer was made to check that the in-
house solutions were comparable to the NEB solution. The hypothesis was 
tested in tube to determine which salt was necessary for amplification.  
The positive amplification results showed that Buffers 4 and 5 inhibited 
amplification when there was reduced salt. Therefore, these two buffer conditions 
were expected to be recovered in the chip if there was sufficient salt on the PES. 
KCl was required for amplification while ammonium sulfate was not required. To 
test in chip, a condition where there was no amplification without the 
hypothesized salt on the PES was needed, which was Buffers 4 and 5. If there 
was salt on the PES, it could rescue the (failed) amplification reactions in Buffers 
4 and 5. 
 
Table 9: List of lysis buffers tested. 
 










1 NEB Isoamp buffer + + + + + 
2 Housemade Isoamp buffer + + + + + 
3 Buffer 2 without ammonium sulfate + - + - + 
4 Buffer 2 without KCl + + - - - 
5 
Buffer 2 without  
ammonium sulfate 
and KCl 
+ - - - - 
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The gel results and LFS results of the salt rescue experiment confirmed the real-
time results (Figure 89). There was negative amplification for all negative 
samples across buffer conditions, and positive amplification for positive samples 
for Buffers 1-3. The LFS results showed the same results, where negative 
samples had the biotin line only while positive samples had FAM and control 
lines. 
 
Figure 89: Agarose gel and LFS results for salt rescue experiment in tube. 
 
Testing salt rescue hypothesis in alpha prototype chip 
A negative and positive sample was run for each buffer condition on chip. 
Buffers 4 and 5 were expected to be rescued with the salt on the PES leftover 
from the bench extractions. However, the results showed negative amplification 
for all the positive samples (Figure 90). This could be due to insufficient or 
excess salt on the PES which could not recover the amplification ability of the 
buffers. The inhibition could not be easily rescued by removing one concentration 
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of salt from the buffer, so further investigation was performed to elucidate the 
cause of the inhibition. 
 
Figure 90: LFS results for salt rescue experiment on chip. 
 
Lysis buffer components 
Next, I investigated each of the components in the lysis buffer to tease out 
what could be causing inhibition of amplification (Figure 91). For each reaction, 
the washing steps were maintained as 200 µl of 70% ethanol and 100 µl of 100% 
ethanol. For lysis condition 1, no lysis buffer was added. Condition 2 was the 
complete lysis buffer formulation. Condition 3 was GuSCN only, a chaotrope. 
Condition 4 was NaCl only, a salt. The controls in the tube amplified as expected. 
In Condition 1, 2/3 amplified without lysis buffer, showing that ethanol did not 
(completely) inhibit amplification. In Condition 2, 0/3 amplified with complete lysis 
buffer, meaning lysis buffer inhibited amplification. In Condition 3, 1/3 amplified 
with GuSCN only, showing that GuSCN did not (completely) inhibit amplification. 
In Condition 4, 0/3 amplified with NaCl, indicating that NaCl completely inhibited 
amplification. From this experiment, I also found that amplification can occur 
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when there are ethanol washes.
 
Figure 91: Testing lysis buffer components on chip shows that NaCl (4) inhibits 
amplification. 
 
Previously, it was hypothesized from the CTNG HDA Fellowes chip work 
in our lab that one of the components of the Fellowes chip was incompatible with 
ethanol due to ethanol leaching unknown material from the adhesive that 
inhibited HDA amplification. However, this ethanol inhibition does not appear to 
be true for LAMP. 
The next experiments tested centrifuge-dependent lysis off chip (lysis was 
performed in a tube with centrifuge and the resuspended product was applied to 
the chip) and centrifuge-free lysis on chip, as well as with a heated lid to stabilize 
any temperature variations across the chip (Figure 92). Both cases utilized our 
lysis buffer. The different lysis conditions were as follows: 1) centrifuge-
dependent lysis, heated lid, 2) centrifuge-free lysis, heated lid, 3) centrifuge-
dependent lysis, no heated lid, and 4) centrifuge-free lysis, no heated lid. 
Centrifuge-dependent lysis led to more amplification than centrifuge-free lysis 




Figure 92: Centrifuge-dependent and centrifuge-free lysis on the alpha prototype chip 
with heated and unheated lid. 
 
Lysis off chip and washing off chip 
Next, I tested centrifuge-dependent lysis and washing on and off chip 
(Figure 93). The washing conditions were as follows: 1) wash on chip, heated lid, 
2) wash on chip, no heated lid, 3) wash off chip, heated lid, and 4) wash off chip, 
no heated lid. From these experiments, centrifuge-dependent lysis with washing 
on and off chip led to amplification for the HPV16 positive samples. Heated and 
no heated lid were comparable. In this case, however, the reaction time was 1 
hour instead of the usual 45 minutes. The increased reaction time may have 
provided enough time to overcome the inhibitors previously active in the reaction. 
To confirm this result, another experiment was run that included NTC controls for 
the chip as well. 
 
Figure 93: Centrifuge-dependent lysis and washing on and off chip for 1 hour of HPV16 
LAMP with positive samples. 
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There were similar results for washing on and off chip, suggesting the issue with 
amplification may not be with the wash step. Hot plate conditions (heated lid, 
reaction time) and centrifuge-dependent lysis were more important factors for 
amplification. 
The same experiment was repeated with NTC samples (Figure 94). The 
different conditions were 1) centrifuge-free lysis, NTC, 2) centrifuge-free lysis, 
HPV16, 106 cp, 3) centrifuge-dependent lysis, NTC, and 4) centrifuge-dependent 
lysis, HPV16, 106 cp. Centrifuge-free lysis inhibited amplification as expected, but 
centrifuge-dependent lysis samples had NTC amplification after an hour. 
Therefore, the conclusion was to switch from the bench extraction lysis buffer 
and extraction method, which did not have reliable results in centrifuge-
dependent or centrifuge-free forms, to a more established and reliable QIAGEN 
extraction method in order to extract DNA from clinical samples to demonstrate 
clinical feasibility with the alpha prototype chip. 
 
 
Figure 94: Centrifuge-dependent lysis and washing on and off chip for 1 hour of HPV16 
LAMP with negative and positive samples. 
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QIAGEN-extracted samples with alpha prototype chip 
HPV16 LAMP was performed with QIAGEN-extracted clinical samples and 
the products were applied to the alpha prototype chip, bypassing the bench-
extraction method. The purified DNA was previously characterized with our in-
house mPCR and the copy numbers for the HPV16 E7 and RNAseP genes were 
calculated according to internal standards. In addition, the purified DNA was 
used in HPV16 LAMP in tube to ensure it could amplify using LAMP instead of 
PCR conditions.  
After running on the chip, the results for each clinical sample matched the 
positivity of the tube LAMP results (Figure 95). Samples 63, 85, 90, and 102 
amplified for 3/3 replicates, as indicated by a positive FAM line on the LFS, while 
samples 91 and 116, amplified for 1/3 replicates. In the tube LAMP experiment, 
Samples 91 and 116 did not amplify, so the chip results were consistent with the 
tube results. The fact that 1/3 instead of 0/3 replicates amplified suggested that 
the alpha prototype chip could be more sensitive than the tube LAMP in 
identifying positive samples as determined by PCR.  
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Figure 95: QIAGEN-extracted samples amplified in the alpha prototype chip. 
 
More QIAGEN-extracted samples were tested on the alpha prototype chip 
with HPV16 and HPV18 LAMP to demonstrate feasibility of this chip 
configuration to identify these two HPV types (Figure 96). The PCR 
characterization results of these 10 clinical samples were used to compare with 
the chip characterization results. For HPV16 LAMP, 4/5 of the HPV16+ samples 
(128, 142, 188, 201) amplified, but Sample 222 had 2/3 faint FAM lines. All of the 
HPV16 negative samples were negative on the LFS. 
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Figure 96: Additional QIAGEN-extracted samples with HPV16 LAMP on chip. 
 
For HPV18 LAMP, only Sample 128 was positive for HPV18, and this was 
supported by 2/3 of the LFS results (Figure 97). The third replicate of this sample 
had a faint DIG line compared to the other two replicates, and was counted as a 
positive. Therefore, this small subset of clinical samples demonstrates that 
QIAGEN-extracted samples could be amplified and detected with the alpha 




Figure 97: QIAGEN-extracted samples with HPV18 LAMP on chip. 
 
Feasibility study with QIAGEN-extracted samples on alpha prototype chip 
 A chip feasibility study was performed with 52 clinical samples that were 
previously characterized with our in-house mPCR. The lower limits of detection of 
the PCR assay with cloned DNA standards were 103 copies for each target 
(Table 10).  
 
Table 10: LLODs for PCR and chip assays. 
Assay HPV16 DNA LLOD 
HPV18 DNA 
LLOD 
HPV16 LAMP on chip 105 cp n/a 
HPV18 LAMP on chip n/a 105 cp 
HPV16 + HPV18 mPCR in tube 103 cp 103 cp 
 
I compared the chip detection to this PCR gold standard detection with the 52 
samples. The results are summarized in Table 11. 
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Table 11: Clinical sample results using the chip assay or PCR assay. 
 
There were 31 true positives, 19 false negatives, 0 false positives, and 2 true 
negatives. We did not have many HPV16 negative samples in our clinical sample 
bank, which skewed our results. The results were binned by copy number 
because we were operating around our chip LLOD of 105 copies (Table 12).  
 
Table 12: Cumulative sensitivity and specificity of the chip assay with 52 clinical 
samples. 
 
When the samples had 105 copies, the sensitivity and specificity of the chip was 
100%. As the test included samples that had 104 copies, the specificity remained 
at 100%, but there were more false positives because the samples were below 
the LLOD of the chip. Improving the chip to a lower LLOD would increase the 





This work delved into clinical samples and preparation of the clinical 
samples and alpha prototype chip configuration to be used together. There is a 
characterized patient bank of ~60 clinical samples with information about the 
HPV16, HPV18, and RNAseP statuses that can be used for future studies with 
the Fellowes chip or other chip design. These samples can also be used to test 
other amplification and detection assays such as HDA, recombinase polymerase 
amplification (RPA), or electrochemical detection of DNA.  
In Chapter 4, HPV16+18 mLAMP was achieved on chip as two singleplex 
chips for HPV16 LAMP and HPV18 LAMP. In Chapter 5, troubleshooting was 
performed to determine how to improve chip performance with the bench 
extraction method. After many efforts such as increased washing, removing lysis 
off chip, and increasing reaction time, I found that the butanol-based lysis buffer 
still inhibited LAMP. Therefore, QIAGEN extraction was performed to extract and 
obtain purified DNA from the clinical samples. 
Further work is needed to optimize the chip to work with clinical samples 
and the butanol-based lysis buffer and to validate this chip configuration with 
numerous clinical samples. However, this proof-of-concept study provides a good 
starting point and serves as the foundation for further evaluation of the integrated 
molecular diagnostic device for POC detection of HPV16 DNA and HPV18 DNA 
in low-resource settings.  
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Chapter 6: Conclusions and Future Directions 
In my thesis aims, I successfully developed an HPV16+18 multiplexed 
LAMP (mLAMP) assay that could differentially detect HPV16 DNA and HPV18 
DNA on a lateral flow strip. I also designed a new fluorescent imaging workflow 
that can be used to troubleshoot and characterize LAMP assays in addition to the 
conventional methods of restriction digests and agarose gel electrophoresis. New 
HPV16 LAMP primers were designed and characterized with the fluorescent 
workflow, and HPV18 LAMP primers were optimized from a published set. In the 
mLAMP assay, 104 copies of DNA were achieved as the lower limit of detection 
after 30 minutes.  
Two chip designs – the Fellowes chip and the COP chip – were tested to 
determine the optimal chip for LAMP amplification. After much testing and 
optimization of chip fabrication and operation for each chip, the Fellowes chip 
was chosen because it enabled reliable results for LAMP. During translation of 
the mLAMP assay to the Fellowes alpha prototype chip, there was an 
unexpected result of a FAM line appearing for negative samples. This led to 
significant troubleshooting efforts to identify the potential problematic interaction 
between the HPV16 LF-FAM and HPV18 LB-Biotin primers. In the end, the 
mLAMP assay was split to two singleplex LAMP assays for the Fellowes chip to 
circumvent the false positive issue.  
An extraction step was added to the chip to lyse clinical samples, but the 
butanol-based lysis buffer used inhibited LAMP amplification. Therefore, 
 173 
QIAGEN extraction was used off chip for the clinical samples and the purified 
DNA was applied on chip for amplification and detection. This optimized chip 
configuration was used to test a small subset of clinical samples to demonstrate 
the chip’s feasibility in achieving comparable results with PCR in tube. Prior to 
use, the clinical samples were characterized with an in-house mPCR assay to 
determine the copy numbers of HPV16, HPV18, and RNAseP DNA in the 
sample. A summary figure of the multiplexed LAMP assay in tube to chip and 
clinical samples is shown below in Figure 98. 
 
Figure 98: Summary of mLAMP assay in tube to chip and clinical samples. 
 
Future directions involve improving many aspects of the chip, from the 
mLAMP assay to chip operation and fabrication. Although there was not a 
sufficient workaround for the negative sample’s false FAM line, much was 
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learned regarding nonspecific primer interactions. Primer redesign is the most 
obvious route for future work to get the mLAMP assay in one reaction on the 
Fellowes chip, but minimizing nonspecific interactions via chemicals or heat 
could be further explored. 
Several improvements to the Fellowes chip operation can be made and a 
hybrid of the COP and Fellowes chip could be the next iteration of the chip. The 
new beta prototype would ideally have the decreased user pipetting steps and 
easier operation of the COP chip while retaining the simple fabrication and LAMP 
compatibility of the Fellowes chip. The LAMP reagents could be dehydrated on 
paper, and rehydrated upon introduction of the extracted DNA, removing the 
need for cold-chain storage and transport of the temperature-sensitive LAMP 
reagents. The heat source for LAMP could be a resistive heater applied to the 
chip instead of the hot plate to make the chip more portable. In addition, other 
lysis buffer compositions could be examined that are not butanol-based (i.e. 
isopropanol or ethanol) or contain different reagents than the current reagents to 
circumvent inhibition of LAMP. 
My preliminary work showing the ability of QIAGEN-extracted DNA stored 
in the Fellowes chip for 5 days to be amplified suggests that extracted DNA can 
be stored for a time period before LAMP reagents are applied. This implies that 
extraction can be performed at a different time than LAMP and there could be a 
time break in the chip operation, perhaps as the samples travel from remote 
areas to a more central laboratory that has cold-chain supplies.  
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Another area to gain sensitivity improvements to the LAMP reaction is to 
have more sensitive lateral flow strips than the existing ones from UStar 
Biotechnologies. In many of my lateral flow strip results, the darkest line was the 
first FAM line, with the DIG and biotin lines were faint or even missing, a 
phenomenon known as the Hook effect. Missing control or secondary test lines is 
not ideal because it could lead to a misinterpretation or misdiagnosis for a 
patient. The Hook effect can be circumvented by adding more streptavidin beads 
to the conjugate pad by creating custom lateral flow strips in house. I have also 
done some preliminary work exploring other LFS from American Bionostica (NJ, 
USA). Strips A, B, and D were experimental LFS while strip C is the conventional 
BioUstar LFS. HPV16 LAMP was performed with negative (NTC) and positive 
(HPV16, 107 cp) samples, and the amplicons were applied to the various lateral 
flow strips (Figure 99). For Strip A, the NTC test line was comparable to that of C, 
but the FAM test line for the positive sample was fainter than that of C. Strip B 
had very faint control and test lines when compared to those of C. Lastly, Strip D 
had a positive line for the NTC sample, making it unusable. From this work, Strip 
A was the most promising and efforts are currently underway by American 
Bionostica to improve the test line readout for A to be comparable to, if not better 
than, that of C. 
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Figure 99: Testing new LFS with HPV16 LAMP. 
 
After the various aspects of the chip are fully optimized, the chip would 
perform robustly with clinical samples and reliably diagnose HPV16 and HPV18 
in the lab, and efforts would be made to bring the chip to a field setting. The user-
friendliness of the chip would be determined by having untrained personnel 
perform the test. Information about device usability would be obtained and 
incorporated to improve the device design and operation. Ultimately, after proper 
validation, the chip will be taken to the field and tested with patients in low-
resource settings to provide high-risk HPV diagnosis for cervical cancer 
screening. 
Lastly, there are many implications of my work exploring the question: how 
can we better distinguish positive LAMP amplification (beyond the conventional 
methods that are hard to characterize)? The new workflow combining fluorescent 
tags, imaging, and digests was developed to answer this question and provide 
tools for LAMP assay development (Figure 100).  
 177 
 
Figure 100: Implications of fluorescent imaging workflow on LAMP assay development. 
 
First, my system allowed LAMP to be read visually on a lateral flow strip (LFS), 
which is important for POC use. It also enabled sequencing of LAMP products, 
which is typically difficult to do because of the vast amount of products available. 
Lastly, it enables easier multiplex development and characterization with different 
fluorescent tags. The fluorescent workflow simplifies the complexities of positive 
LAMP characterization by helping the assay developer find the needle through 
the haystack of LAMP products. Knowing the sources of product is important to 
properly characterize LAMP assays. Researchers can use this tool to better 
characterize and understand the molecular mechanisms at play as they develop 
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